

University of Groningen

## Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers

Elsakov, Pavel; Foretova, Lenka; Goetz, Petr; de Groot, Johannes W. B.; van der Graaf, Winette T. A.; Guler, Gulnur; Huebner, Kay; Haites, Neva E.; Hamann, Ute; Ho, Judy

*Published in:*

Hereditary cancer in clinical practice

*DOI:*

[10.1186/1897-4287-5-3-119](https://doi.org/10.1186/1897-4287-5-3-119)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2007

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Elsakov, P., Foretova, L., Goetz, P., de Groot, J. W. B., van der Graaf, W. T. A., Guler, G., ... IC BCSG (2007). Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers. *Hereditary cancer in clinical practice*, 5(3), 119-143. <https://doi.org/10.1186/1897-4287-5-3-119>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Discussion on the use of taxanes for treatment of breast cancers in *BRCA1* mutations carriers

**Pavel Elsakov**

**Vilnius University, Institute of Oncology, Lithuania**

*BRCA1*-associated cancers differ from non-hereditary cancers for many factors, including somatic mutation. It can be a subject of discussion that the natural history and response to treatment also may differ between the hereditary and sporadic subgroups. Three frequent *BRCA1* mutations (5382insC, 4153delA, C61G) in the Baltic countries (Lithuania, Latvia, Byelorussia and Poland) open a way for the chip test to select a subgroup from women with breast cancer. These women with *BRCA1* breast cancer have a chance to get adequate treatment, including neo-adjuvant chemotherapy. So far many retrospective studies of survival, that used the same gold standard treatment for women with *BRCA1* breast cancer and for women without a mutation, have not found a difference between these groups. Some studies show a worse survival result in women with a *BRCA1* mutation than women without the mutation.

Byrski et al. in the article *Response to neo-adjuvant chemotherapy in women with BRCA1 positive breast cancer* confirm that use of taxane in neo-adjuvant chemotherapy is not effective for treatment in women with positive *BRCA1* breast cancer.

Independently, on a small number of studied patients, the results and conclusions of the study make it possible to form the opinion that it is really necessary to change the view on combination of chemotherapy (including neo-adjuvant) with other treatment methods of women with *BRCA1* positive breast cancer. Another conclusion: there is no difference in response between negative oestrogen receptor (ER) and positive ER to taxane neo-adjuvant chemotherapy. So we need to develop a strategy of hereditary cancer identification by *BRCA1* mutation testing only after that to consider using taxane in neo-adjuvant chemotherapy.

**Lenka Foretova**

**Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic**

These results are very interesting and important. In the Czech Republic (CR), we have a large series of women with breast cancer tested for *BRCA1* and *BRCA2* mutations. The situation with genetic testing is more complicated in the CR since the germline mutations are scattered through the whole *BRCA1* or *BRCA2* gene and complete testing of both genes is required. We have not done any analysis of retrospective data on neo-adjuvant chemotherapy in *BRCA1* carriers with breast cancer in our cohort of tested patients yet, and thus we cannot discuss your results. But my suggestion is to get together a large retrospective study of all *BRCA1* positive breast cancer patients within Europe (or elsewhere) and have really very conclusive results. The data are available in each centre and a large multinational study should not be a big problem.

Your suggestion of having all breast cancer patients tested for *BRCA1* mutations before chemotherapy is unrealistic in the Czech Republic. The testing requires rather complicated analysis of the whole gene and the insurance would not pay for it. So far we have tested women with breast cancer if they fulfil our testing criteria, sporadic breast cancer diagnosed below 35, bilateral sporadic breast cancer diagnosed below 50 and familial forms of breast/ovarian cancer. The time needed for the testing is quite long so women do not have the results before chemotherapy is started.

The most frequently used chemotherapy regimen for breast cancer in Masaryk Memorial Cancer Institute in Brno, Czech Republic, is based on anthracyclines. In some high-risk cases taxanes are used in combination with anthracyclines. Taxanes are mostly used for relapses when *BRCA1* results are already available in indicated cases.

For the differentiation of the chemotherapy according to the *BRCA1* status we suggest replicating your results in a large multicentre case/control study. We are ready to join it.

## Petr Goetz

**Institute of Biology and Medical Genetics of 2<sup>nd</sup> Medical School and of University Hospital Motol, Charles University Prague, Czech Republic, e-mail: petr.goetz@lfmotol.cuni.cz**

### Opinion of editorial board member

The data presented in Bryski et al.'s paper *Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancer* seem to be interesting and probably promising for effective breast cancer therapy. The authors concluded that *BRCA1* carriers of three *BRCA1* founder mutations in Poland are less sensitive to docetaxel in neoadjuvant therapy in comparison with *BRCA1* normal controls. Presented data match previous results on cell lines. A few clinical studies are not quite unequivocal. In the study tumour size was determined in all patients, also by mammography, which is questionable in *BRCA1* mutation carriers having in mind the role of *BRCA1* protein in repair processes.

The course of various types of breast cancers and the sensitivity to the different therapeutic procedures depends on individually heterogeneous number of expressed genes, which complicates such type of studies. Anyway, the presented results of the Polish population should motivate an international multicentric study to get more reliable, possibly population-dependent results.

Clinical impact and authors' recommendation of *BRCA1* testing in each woman with a newly diagnosed breast cancer and modification of neo-adjuvant chemotherapy associated with that is appropriate for a well organized system of breast cancer management as it is in Poland. It will also represent the continuation of the study and getting more numerous samples of patients.

## Johannes W.B. de Groot<sup>1</sup>, Winette T.A. van der Graaf<sup>2</sup>

**<sup>1</sup>Department of Internal Medicine, Isala Klinieken Zwolle, the Netherlands, e-mail: j.w.b.de.groot@isala.nl**

**<sup>2</sup>Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands**

### *BRCA1* and treatment decisions in breast cancer

The focus of attention after surgical resection of breast cancer is to establish which patients will gain

benefit from adjuvant therapies such as chemotherapy, hormonal treatment, targeted therapy and radiotherapy. Presently, treatment decisions are made based on the age and menopausal status of the patient and histopathological features of the tumour. Molecular markers currently used to predict treatment response include oestrogen receptor (ER)- $\alpha$ , progesterone receptor (PgR), and the epidermal growth factor receptor HER2/neu. The current strategy aimed at improving the outcome of breast cancer patients is mainly based on the identification of additional biomarkers that could help in the prediction of response to specific systemic anti-tumour therapy.

There is no clear agreement on the importance of individual molecular markers or their clinically relevant levels. Recent studies demonstrated that the genetic makeup or gene-expression profile of a tumour is a strong determinant of its susceptibility to develop distant metastases [1, 2]. Classification of patients into high-risk and low-risk subgroups on the basis of a gene-expression profile may be a useful means of guiding adjuvant therapy in patients with breast cancer. Several prospective, randomised studies such as the MINDACT (**M**icroarray **I**n **N**ode negative **D**isease may **A**void **C**hemo**T**herapy) trial (EORTC Protocol 10041-BIG 3-04) that compare such gene-expression signatures with a common clinical-pathological prognostic tool in selecting patients for adjuvant chemotherapy are underway.

In addition, the tumour suppressor gene *BRCA1* might be promising as a predictive biomarker. However, the question remains whether there are sufficient compelling data to add routine *BRCA1* testing into clinical practice to tailor current chemotherapy regimens in such a way that maximum benefit is gained with minimal exposure to unnecessary drugs.

To answer this question, it is necessary to establish whether the presence of a germline *BRCA1* mutation or reduced *BRCA1* expression levels actually affects the prognosis of patients with breast cancer. It is estimated that 5-10% of all breast cancer cases are hereditary, and *BRCA1* and *BRCA2* have been identified as being accountable for 21-40% of these cases [3, 4]. Somatic *BRCA1* mutations are hardly ever observed in sporadic breast tumours; however, up to 30% of cases have abridged expression of *BRCA1* mRNA and protein due to epigenetic silencing of the *BRCA1* gene [5-7].

Breast cancers in patients with *BRCA1* mutations mostly occur in younger women, and such tumours are often poorly differentiated, have a basal-like phenotype characterised by the expression of basal epithelial markers such as CK5 and CK14, and lack ER, PgR and HER2/neu receptors. Furthermore, *TP53* mutations occur frequently in *BRCA1*-mutated tumours [8]. These

features may suggest that hereditary breast cancer has an unfavourable outcome. However, a randomised or prospective study between patients with sporadic breast cancer and *BRCA1* mutation carriers with breast cancer to investigate the prognostic value of *BRCA1* is yet to be performed. In addition, the studies that have addressed the prognostic impact of germline *BRCA1* mutations [reviewed in reference 9] vary with respect to different confounding factors such as numbers of patients, selecting and testing of cases and control groups, applied therapy, ethnic background or specific mutations. Consequently, no definitive conclusions can be drawn about the prognosis of breast cancer patients with germline *BRCA1* mutations in relation to sporadic breast cancers with or without epigenetic silencing of *BRCA1*. Until now, except for increased risk of contralateral breast cancer, the presence of a *BRCA1* mutation does not seem to offer supplementary prognostic information to ER, PgR, and HER2/neu [9, 10]. Furthermore, it is unclear as to whether sporadic tumours with reduced expression of *BRCA1* behave just as *BRCA1*-mutant tumours.

Although the prognostic value of *BRCA1* remains to be determined, *BRCA1* status may influence the response to chemotherapy. It is evident that *BRCA1* can regulate differential sensitivity to diverse classes of cytostatic agents *in vitro*. The absence of *BRCA1* may result in increased sensitivity to DNA damage-based chemotherapy, whereas the presence of *BRCA1* endorses an increase in sensitivity to antimicrotubule agents [11]. Initial indications that *BRCA1* may predict response to chemotherapy were obtained from several small retrospective studies that evaluated response to neoadjuvant anthracycline-based regimens. These studies suggested that *BRCA1*-mutant tumours were highly sensitive to anthracycline-based chemotherapy and that patients with *BRCA1*-related breast cancer gained more benefit from chemotherapy than patients that were non-carriers [12, 13]. However, a recent, fairly large, Israeli study with comparatively homogeneous treatment regimens that were chosen without knowledge of mutational status found that influence of a *BRCA1* mutation on the outcome of DNA damage-based chemotherapy was not statistically significant [10]. Therefore, the clinical evidence to date suggests that the additional benefit from DNA damage-based chemotherapy for patients with *BRCA1* germline mutations compared to non-carriers is, at best, limited.

In sporadic breast cancer cases, there is conflicting evidence as to whether tumours with epigenetic inactivation of *BRCA1* will gain benefit to DNA damage-based chemotherapy. To date, studies examining reduced *BRCA1* mRNA levels in sporadic breast cancer and its

role in chemotherapy response have shown results that contradict preclinical data [11]. In one specific study, only 32% of tumours with low *BRCA1* mRNA levels were found to respond to DNA damage-based chemotherapy compared with a 65% response rate in tumours with high levels of *BRCA1* mRNA [14].

There have been only a small number of studies examining *BRCA1* in response to taxane-based chemotherapy in breast cancer. A recent multi-centre study from Poland evaluated response to neo-adjuvant chemotherapy in 44 women with *BRCA1*-positive invasive breast cancer matched to 41 *BRCA1*-negative controls. *BRCA1* carriers were less likely to respond to neoadjuvant docetaxel in combination with doxorubicin than non-carriers [15]. In contrast, a study in 25 Japanese women with advanced breast cancer reported that low levels of *BRCA1* tended toward increased sensitivity to neoadjuvant docetaxel, but this did not reach statistical significance [16]. However, both studies involved relatively few patients and neoadjuvant non-standardised treatment protocols. Furthermore, to predict response to docetaxel, various other biological parameters related to: (1) efflux (p-glycoprotein) and metabolism (CYP3A4); (2) beta-tubulin (somatic mutation of beta-tubulin and changes in levels of beta-tubulin isotypes); (3) cell cycle (*HER2* and *Aurora-A*); and (4) apoptosis (*TP53*, *BCL2* and thioredoxin) have to be taken into account [17].

It is also important to bear in mind that known susceptibility genes account for less than 25% of the familial risk of breast cancer, and the residual genetic variance is likely to be due to variants conferring more moderate risks [18]. In all likelihood, *BRCA1* is not the only breast cancer susceptibility gene. Recently five novel breast cancer susceptibility loci were identified, and this study demonstrated conclusively that some of the variation in breast cancer risk is due to common alleles [19]. Especially due to the infrequent occurrence of *BRCA1* mutations, it would not seem reasonable or economically feasible to test every woman with breast cancer for either mutations in *BRCA1* or expression of the protein in the tumour.

In conclusion, there is currently no place for routinely testing every new breast cancer for germline mutations in *BRCA1* or *BRCA1* expression in the tumour. Furthermore, until results of prospectively executed studies appear that underscore the importance of *BRCA1* status, the present data are insufficient to support a *BRCA1*-based policy when assigning adjuvant treatment.

## References

1. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T,

- Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 2002; 347: 1999-2009.
2. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF. The prognostic role of a gene signature from tumorigenic breast-cancer cells. *N Engl J Med* 2007; 356: 217-226.
  3. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL. *BRCA1* mutations in women attending clinics that evaluate the risk of breast cancer. *N Engl J Med* 1997; 336: 1409-1415.
  4. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in *BRCA1* and *BRCA2*. *Science* 2003; 302: 643-646.
  5. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of *BRCA1* accelerates growth and is often present during sporadic breast cancer progression. *Nat Genet* 1995; 9: 444-450.
  6. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the *BRCA1* CpG island promoter is associated with decreased *BRCA1* mRNA in sporadic breast cancer cells. *Oncogene* 1998; 17: 1807-1812.
  7. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the *BRCA1* gene in sporadic breast cancer. *Breast Cancer Res* 2006; 8: R38.
  8. Narod SA, Foulkes WD. *BRCA1* and *BRCA2*: 1994 and beyond. *Nat Rev Cancer* 2004; 4: 665-676.
  9. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of *BRCA1/2* associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. *Eur J Cancer* 2007; 43: 238-257.
  10. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. Clinical outcomes of breast cancer in carriers of *BRCA1* and *BRCA2* mutations. *N Engl J Med* 2007; 357: 115-123.
  11. Mullan PB, Gorski JJ, Harkin DP. *BRCA1* – a good predictive marker of drug sensitivity in breast cancer treatment? *Biochim Biophys Acta* 2006; 1766: 205-216.
  12. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancer. *J Med Genet* 2002; 39: 608-610.
  13. Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD. Impact of germline *BRCA1* mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. *Cancer* 2003; 97: 527-536.
  14. Egawa C, Motomura K, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Inaji H, Koyama H, Noguchi S. Increased expression of *BRCA1* mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. *Breast Cancer Res Treat* 2003; 78: 45-50.
  15. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Swiez M, Wisniowski R, Siolek M, Narod SA, Lubinski J. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers; the Polish Hereditary Breast Cancer Consortium. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].
  16. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Decreased expression of *BRCA2* mRNA predicts favorable response to docetaxel in breast cancer. *Int J Cancer* 2001; 95: 255-259.
  17. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. *Cancer Sci* 2006; 97: 813-820.
  18. Walsh T, King MC. Ten genes for inherited breast cancer. *Cancer Cell* 2007; 11: 103-105.
  19. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struwing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R; SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odeh F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schürmann P, Dörk T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X; kConFab; AOCs Management Group, Mannervaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* 2007; 447: 1087-1093.

## Gulnur Guler<sup>1</sup>, Kay Huebner<sup>2</sup>

<sup>1</sup>Department of Pathology, Hacettepe University, Ankara, Turkey, e-mail: gulnurguler@yahoo.com

<sup>2</sup>Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, Oh, USA e-mail: kay.huebner@osumc.edu

This observational study provides important clues about treatment options of *BRCA1* carriers and sporadic basal-like breast cancers. There is an urgent need to search for treatment alternatives for patients who have “triple negative” breast tumours, as currently this group of patients is without the advantages of traditional or recently developed targeted therapies. The majority of “triple negative” breast tumours are basal-like cancers that have inactivated *BRCA1* function, and chemotherapy is usually the only treatment option for them. So, it is important and practical first to test the sensitivity of available agents while trying to develop new drugs that are especially effective for basal-like cancers.

As mentioned in the report by Byrski et al. (*Br Can Res Treat* 2007), one more problem is whether there are different subgroups with different treatment responses in basal-like cancer, such as cases with *BRCA1* mutation or cases with both basaloid and myoepithelial differentiation. Another problem is to develop testing methods to select patients who are sensitive to different therapies. The simplest widely available method is immunohistochemistry. There are some recently published studies showing that immunohistochemical panels are useful to

determine basaloid differentiation of breast tumours. It is also important to find out whether there is a difference in response to the treatments between patients with inactivated *BRCA1* function without or with *BRCA1* mutation. The study of Byrski et al. shows that taxane-based neoadjuvant treatment is ineffective for *BRCA1* carriers. Interestingly, the specific *BRCA1* mutation did not seem to be the determining factor in response to docetaxel neo-adjuvant therapy, since individual patients with the same mutation could be responders or non-responders. It will be important to extend this study to a large group of sporadic basaloid breast tumours to understand whether they also have similar features.

### **Neva E. Haites**

**The University Court of the University of Aberdeen,  
Department of Medicine, Foresterhill, United Kingdom,  
e-mail: n.haites@abdn.ac.uk**

Many thanks for letting me see this paper. It looks very interesting and potentially important. Perhaps you now need to have a prospective trial to further clarify the importance of the differences in outcome.

I think it would also be important to have the opinion of a Clinical Oncologist in this area.

### **Ute Hamann**

**Deutsches Krebsforschungszentrum Molecular Genetics  
of Breast Cancer, Germany, e-mail: u.hamann@dkfz-  
heidelberg.de**

Neoadjuvant therapy is a valid option both for advanced breast cancer and operable breast cancer. In addition, it improves surgical treatment by increasing the rate of breast conservation surgery, which minimises psychological distress for patients fearing mastectomy.

In a recent observational trial conducted among Polish breast cancer patients the response to different neoadjuvant chemotherapy regimens was evaluated in *BRCA1* mutation carriers and non-carrier controls. Interestingly, among women treated with doxorubicin in combination with docetaxel the number of responders was lower in those carrying a *BRCA1* mutation than in those without: six of 15 *BRCA1* carriers responded to treatment compared to 12 of 12 non-carriers. No difference in the proportion of non-responders in carriers and non-carriers was found among women who only received DNA-damaging chemotherapies. Thus, these data suggest that *BRCA1* mutation status is helpful in selecting patients who may benefit from neoadjuvant doxorubicin and docetaxel chemotherapy.

The results of the present study are promising because they provide the first evidence that neoadjuvant treatment with doxorubicin in combination with docetaxel may not be an efficient treatment for *BRCA1*-associated breast cancer, implying that alternative neoadjuvant treatments should be offered to these women. They also support the notion that expression of normal *BRCA1* protein appears to be required for clinical response to the mitotic spindle poison docetaxel. However, due to the small size of this study, the results have to be considered as preliminary. When being confirmed in other larger studies, *BRCA1* mutation status may be useful as a predictive marker for chemosensitivity/resistance to neoadjuvant treatment with doxorubicin and docetaxel. A better understanding of the pharmacogenetics in *BRCA1* carriers will allow physicians to individualize neoadjuvant treatment in these women.

### **Judy Ho**

**Hereditary Gastrointestinal Cancer Registry, Hong Kong  
and Department of Surgery, University of Hong Kong Medical  
Centre, Queen Mary Hospital, Hong Kong**

The article by Byrski et al. is a case-control study (44 cases matched with 41 controls) conducted in 18 different hospitals throughout Poland during the study period. Subjects (both cases and controls) were unselected, early-onset incident breast cancer patients undergoing neoadjuvant chemotherapy using a wide range of chemotherapeutic regimens according to current local practice. These subjects were stratified according to their *BRCA1* mutation status. Mutational analysis was carried out on three common founder mutations in the *BRCA1* gene in Poland.

The outcome indicator of chemotherapeutic response used in this study was the difference in tumour size and lymph node status (pretreatment vs. post-treatment) which served as a surrogate indicator of survival rates (on the assumption that rates of complete response correlate well with survival rates). In this study, the authors found that *BRCA1* mutation carriers had an inferior response to docetaxel-containing neoadjuvant chemotherapy compared with non-carriers.

Although the findings of this current study corroborate previous results on cell lines, the study methodology (uncontrolled observational study), the small sample size and the uncontrolled chemotherapeutic regimens used limited the power of this study. Moreover, as quoted by the authors, various uncontrolled clinical studies (by Chappius et al., Delaloge et al. and Rouzier et al.) on similar topics yielded results contradictory with the current study.

Therefore, further clinical studies, preferably using controlled data (for example, patients enrolled in a randomized controlled trial of breast cancer chemotherapy or neoadjuvant chemotherapy), to compare the response to chemotherapeutic agents as stratified by *BRCA1* mutation status, are required to validate the findings of this study. Otherwise, it is premature to make any firm recommendation regarding the routine use of *BRCA1* mutation status as a predictor of the response to and as a guide to the choice of chemotherapeutic agents in breast cancer.

## Evgeny N. Imyanitov

**N.N. Petrov Institute of Oncology, St. Petersburg, Russia,  
e-mail: [evgeny@imyanitov.spb.ru](mailto:evgeny@imyanitov.spb.ru)**

### Choice of chemotherapy for breast cancer treatment: will BRCA testing help?

Breast cancer (BC) remains the only cancer type for which molecular characterization of the tumour is an absolute prerequisite for consideration of therapeutic options. However, the use of appropriate tests is limited to the planning of targeted therapies, and includes determination of hormone receptor status for anti-oestrogenic interventions as well as analysis of HER2 activation for administration of Herceptin. So far, there is no approved laboratory procedure helping to select the best regimen for chemotherapy; therefore the choice of cytotoxic compounds is based mainly on statistical probability of tumour response. Several promising observations have been reported in this field, for example an apparently reproducible association between amplification and/or overexpression of the topoisomerase II- $\alpha$  (TOP2A) gene and BC sensitivity to anthracyclines [1]. Nevertheless, the progress in identification of molecular predictors of BC response to cytotoxic drugs is surprisingly slow when compared to some other tumour types, e.g. colon cancer. Perhaps relatively high response rates of newly diagnosed breast cancers to any of the standard treatment schemes (CMF, AC, FAC, AT, etc.) decrease the motivation to individualize BC chemotherapy.

Byrski et al. [2] have recently reported fascinating results on the lack of sensitivity of *BRCA1*-related breast carcinomas to the best available cytotoxic combination, namely AT (anthracyclines/taxanes). In their study as many as 9 out of 15 *BRCA1* mutation carriers failed to respond to neoadjuvant therapy by docetaxel and doxorubicin, while all 12 non-carriers demonstrated partial response. Non-taxane combination therapies led to a 100% response rate in 29 *BRCA1*-associated cases, although

treatment of non-carriers was also outstandingly successful (27 responses in 29 patients, 93%). The results of this study are in perfect agreement with *in vitro* data which show resistance of *BRCA1*-deficient breast cancer cell lines to taxanes [3].

While distinct aspects of biology and clinical behaviour of *BRCA1*-related tumours are the subject of intensive research, the report of Byrski et al. [2] is only the second article devoted to comparative analysis of responses to chemotherapy in carriers vs. non-carriers. Previously, Chappuis et al. [4] studied the effect of anthracycline-based therapy and observed exceptionally high rates of clinical and pathological complete responses in patients with either *BRCA1* or *BRCA2* mutation. In addition, Warner et al. [5] published a case report on the unusually rapid complete clinical and pathological response of *BRCA1*-related BC after only 2 cycles of epirubicin-containing scheme.

If replicated in independent studies, the observation of Byrski et al. [2] may have broad practical implications. Possibly, all breast cancer patients for whom neoadjuvant, adjuvant or first-line taxane-containing therapy is considered as an option have to be screened against *BRCA1* mutation, and the mutation carriers should be offered an alternative cytotoxic scheme. While BC cases from communities with a strong founder effect (Poland, Russia, Ashkenazi Jews, etc.) require only a limited number of non-expensive PCR tests, full sequence analysis of the *BRCA1* gene has to be performed in most of the world [6]. Although the latter option does not look realistic at present, it may eventually prove to be cost-efficient by optimizing the spending of highly expensive taxanes and improving the overall results of BC treatment.

Of course, caution must be taken when interpreting the data of Byrski et al. [2]. The main difficulty is related to the low sample size. It is beyond doubt that evaluation of the predictive role of *BRCA* genes requires multicentre research efforts. Given the relatively high proportion of *BRCA1* carriers among BC cases, frequent use of both taxane-containing and non-taxane drug combinations, as well as significant number of yet chemonaive BC patients starting either neoadjuvant therapy or first-line therapy against metastatic disease, an appropriate validation study may be performed within several months.

### Acknowledgements

This work is supported by INTAS (grant 05-1000008-7870), the Russian Agency for Science and Innovations (grant 02.512.11.2101), and the Russian Federation for Basic Research (grant 07-04-91000-AFa).

## References

1. Imyanitov EN, Moiseyenko VM. Molecular-based choice of cancer therapy: realities and expectations. *Clin Chim Acta* 2007; 379: 1-13.
2. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers. *Breast Cancer Res Treat* 2007 May 10; [Epub ahead of print].
3. Chabaliere C, Lamare C, Racca C, Privat M, Valette A, Larminat F. *BRCA1* downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. *Cell Cycle* 2006; 5: 1001-1007.
4. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancer. *J Med Genet* 2002; 39: 608-610.
5. Warner E, Trudeau M, Holloway C. Sensitivity of *BRCA1*-related breast cancer to neoadjuvant chemotherapy: practical implications. *Breast J* 2003; 9: 507-508.
6. Neuhausen SL. Founder populations and their uses for breast cancer genetics. *Breast Cancer Res* 2000; 2: 77-81.

**Arvids Irmejs<sup>1</sup>, Gunta Purkalne<sup>2</sup>,  
Marianna Bitina<sup>1</sup>, Andris Gardovskis<sup>1</sup>,  
Janis Gardovskis<sup>1</sup>**

**<sup>1</sup>Riga Stradins University, Hereditary Cancer Institute, Riga, Latvia, e-mail: hci@stradini.lv**

**<sup>2</sup>Pauls Stradins Clinical University Hospital, Department of Medical Oncology and Radiotherapy, Riga, Latvia**

At first we would like to recognize the authors for a very interesting and well structured study, which essentially contributes to attempts of more individualized and effective breast cancer therapy.

Preparing the opinion, we were able to track the chemotherapy regimens for 23 of our *BRCA1* positive breast cancer cases from Daugavpils regional oncology hospital. Only in 3 cases was taxane treatment used, in all cases in an adjuvant setting, when disease progression (distant metastasis) was detected. In 2 cases disease progressed in spite of taxane treatment (death and new distant metastasis respectively). In the last case taxanes were followed by anthracycline treatment and remission of the disease was achieved. However, the effectiveness of taxanes in this case is difficult to evaluate.

5/19 presently published clinical trials on the role of adjuvant taxane treatment in breast cancer compare their effect with anthracyclines [1] and there is no clear evidence that taxanes are more effective than anthracycline regimens in adjuvant breast cancer treatment. Therefore in many centres taxanes are not used as a 1st line treatment and their role still has to be defined more accurately.

From 1998 to 2000, 26 breast cancer cases in Latvia underwent neoadjuvant treatment with AT (taxol instead of docetaxel) regimen and partial or complete radiological response was observed in 28%. Pathological response was detected only in 1 case. *BRCA1* was not tested at that time.

Presently there is no clear evidence for the superiority of neoadjuvant chemotherapy of any regimen for survival of breast cancer patients and its main objective is reduction of tumour size to perform breast conserving treatment. Thus it is clear that the finding of the authors potentially could affect much more women deciding on their adjuvant therapy than neoadjuvant treatment.

The study of Byrski et al. probably also brings the message that taxanes should not be used as a 2<sup>nd</sup> line adjuvant therapy for *BRCA1* positive breast cancers (in case of disease progression) if further evidence from other centres is achieved.

Reviewing available preclinical and clinical data on docetaxel effectiveness in *BRCA1* positive breast cancer cases, many issues are still uncertain and require further evaluation.

It would be interesting to compare survival data in different chemotherapy regimen subgroups, in order to evaluate the ultimate outcome of therapy. It would also be interesting to extend the study comparing docetaxel effect in *BRCA1* carriers/noncarriers in an adjuvant setting.

The possibility of a multicentre clinical trial comparing docetaxel vs. other chemotherapy regimens should be evaluated in populations where *BRCA1* testing is straightforward and economically effective. As taxane use in breast cancer is still rather centre dependent, in our opinion it would be possible to collect enough cases in both arms.

Summarizing our opinion, we consider it is time to offer each woman with newly diagnosed breast cancer the option of *BRCA1* testing before the decision about multimodal therapy, where it is financially (in populations with a founder effect like Poland, Norway, Latvia etc.) or medically (criteria of hereditary breast cancer) justified. This is further supported by other features specific to the treatment of *BRCA1* positive breast cancers such as the decision about breast conservative therapy vs. mastectomy, surgical (salpingoophorectomy) vs. medical therapy (GnRH) in receptor positive cases of fertile age, and others. At the same time there is no level I or A evidence-based confirmation for such clinical practice and this makes the introduction of routine *BRCA1* testing in national guidelines still rather problematic. Accordingly, financing of pre-therapy *BRCA1* testing from the state budget would be difficult to justify.



We also share the opinion that it is time to differentiate neoadjuvant as well as adjuvant chemotherapy depending on the presence or absence of a mutation in *BRCA1* as there are alternative evidence-based comparably effective chemotherapy regimens available. Preferably it should be done under clinical trials (or at least very careful data recording and analysis) in order to obtain conclusive evidence on the issue as soon as possible.

## References

1. Estévez LG, Muñoz M, Alvarez I, Fernández Y, García-Mata J, Ruiz-Borrego M, Tusquets I, Seguí MA, Rodríguez-Lescure A, Adrover E, Lluch A. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. *Cancer Treat Rev* 2007; Jun 8 [Epub ahead of print].

**Youlia M. Kirova<sup>1</sup>, Alain Fourquet<sup>1</sup>,  
Jean-Yves Pierga<sup>2</sup>,  
Dominique Stoppa-Lyonnet<sup>3</sup>  
for the IC-BOCRSG and IC-BCSG**

<sup>1</sup>Department of Radiation Oncology, Institut Curie, Paris, France

<sup>2</sup>Department of Medical Oncology, Institut Curie, Paris, France

<sup>3</sup>Department of Genetics, Institut Curie, Paris, France,  
e-mail: dominique.stoppa-lyonnet@curie.net

IC-BOCRSG: Institut Curie – Breast Ovary Cancer Risk Study Group

IC-BCSG: Institut Curie – Breast Cancer Study Group

**Responses to neoadjuvant treatment in *BRCA1/2* mutation carriers and familial cases: short comment**

The recently published paper by Byrski et al. [1] addressed a major question regarding the response to chemotherapy of breast tumours occurring in women carrying a germline *BRCA1* mutation. Forty-four carriers who received neoadjuvant chemotherapy were selected through screening for three founding *BRCA1* Polish mutations in a series of 3484 women affected with breast cancer. Only 41 age and hospital matched controls were selected among the same set of patients. In this retrospective study, cases and controls experienced different protocols of chemotherapy. The authors reported a worse response rate in *BRCA1* carriers as compared to non-carriers (80 vs. 95%,  $p=0.05$ ) that they attributed to a lack of sensitivity to docetaxel in carriers.

These results are surprising because of a couple of facts published in the literature.

Since the *BRCA1* protein is involved in the repair of DNA damage, including double-strand breaks induced by radiotherapy and chemotherapy, advanced breast

cancers too large to be treated upfront with breast-conserving surgery could be more chemo- or radiosensitive in mutation carriers than in non-carriers [2]. Higher proliferation in *BRCA1* mut+ tumours, and their related patterns such as high grade and lack of oestrogen receptor expression, represents one mechanism by which *BRCA1* mut+ tumours are more sensitive to treatment. Another mechanism might be related to the loss of bcl-2 expression in *BRCA1* mut+ tumours, thus increasing apoptosis in response to treatment [3]. A gene-expression profile study suggests that *BRCA1* mut+ tumours display increased expression of genes associated with inducing apoptosis, and decreased expression of genes associated with suppressing apoptosis [4]. In clinical practice, Delaloge et al. [5] showed in a small study very high response rates to anthracycline and cyclophosphamide chemotherapy in *BRCA1* carriers. Chappuis et al. [6] reported that *BRCA1/2* carriers showed a better clinical response rate to neoadjuvant chemotherapy than non-carriers. The sensitivity to chemotherapy was confirmed by others studies [7-9]. Indeed, Robson et al. showed that the adjuvant treatment could modify the prognosis of these patients [10]. The authors confirmed with this study that the poor prognosis of *BRCA1* mut+ tumours described in numerous series [11-14] is mitigated by adjuvant chemotherapy [10].

In addition, the impact of adjuvant radiotherapy was shown in 2 studies; with a median 9 and 10-year follow-up after breast cancer treatment, the rate of breast recurrence was not higher in *BRCA1* and *BRCA2* mutation carriers than in patients without family history, despite more aggressive tumour features and a higher risk of contralateral breast cancer [15, 16].

As mentioned by Byrski et al. [1] and other studies, a good sensitivity to chemotherapy and radiotherapy was expected in *BRCA1* mut+ tumours according to the role of *BRCA1* in DNA repair [2]. In addition, good *BRCA1* mut+ tumour sensitivity to taxanes, mitotic spindle poisons, might also be expected since a recent role of *BRCA1* has been reported in mitotic spindle assembly [17].

The study by Byrski et al. [1] is interesting but its conclusions must be confirmed by larger retrospective studies or ideally by large prospective multicentre studies. Indeed, the question is of major interest due to its clinical importance: early diagnosis by MRI, a multidisciplinary approach, and chemo- and radiotherapy may remain a strong alternative to the prophylactic mastectomy option.

## References

1. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M,

- Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].
2. Gudmundsdottir K, Ashworth A. The roles of *BRCA1* and *BRCA2* and associated proteins in the maintenance of genomic stability. *Oncogene* 2006; 25: 5864-5874.
  3. Freneaux P, Stoppa-Lyonnet D, Mouret E, Kambouchner M, Nicolas A, Zafrani B, Vincent-Salomon A, Fourquet A, Magdelenat H, Sastre-Garau X. Low expression of *bcl-2* in *BRCA1*-associated breast cancers. *Br J Cancer* 2000; 83: 1318-1322.
  4. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruber S, Loman N, Johannsson O, Olsson H, Sauter G. Gene-expression profiles in hereditary breast cancer. *N Engl J Med* 2001; 344: 539-548.
  5. Delaloge S, Pelissier P, Kloos I, et al. *BRCA1*-linked breast cancer is more highly chemosensitive than its *BRCA2* linked or sporadic counterparts. Program and abstracts of the 27<sup>th</sup> Congress of the European Society for Medical Oncology; October 18-22, 2002; Nice, France. Abstract 120.
  6. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancers. *J Med Genet* 2002; 39: 608-610.
  7. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storf-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struwing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF. Multifactorial analysis of differences between sporadic breast cancers and cancers involving *BRCA1* and *BRCA2* mutations. *J Natl Cancer Inst* 1998; 90: 1138-1145.
  8. Robson M, Levin D, Federici M, Satagopan J, Bogolmyn F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K. Breast conservation therapy for invasive breast cancer in Ashkenazi women with *BRCA* gene founder mutations. *J Natl Cancer Inst* 1999; 91: 2112-2117.
  9. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Krieger M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from *BRCA2*-, *BRCA1*- and non-*BRCA1/2* families as compared to sporadic breast cancer cases. *Eur J Cancer* 2007; 43: 867-876.
  10. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on *BRCA1/BRCA2* mutation status and administration of adjuvant treatment. *Breast Cancer Res* 2004; 6: R8-R17.
  11. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelénat H, Pouillart P, Vincent-Salomon A, Fourquet A, Asselain B. Familial invasive breast cancers: worse outcome related to *BRCA1* mutations. *J Clin Oncol* 2000; 18: 4053-4059.
  12. Kirova YM, Fourquet A, Savignoni A, Sigal-Zafrani B, Stoppa-Lyonnet D for the Institut Curie Breast Cancer Study Group. Risk of second non breast malignancies (SNBM) in relation to *BRCA1* and *BRCA2* mutation status following breast-conserving surgery and radiotherapy. *Am J Immunology* 2006; 2: 61-63.
  13. Robson M, Levin D, Federici M, Satagopan J, Bogolmyn F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K. Breast conservation therapy for invasive breast cancer in Ashkenazi women with *BRCA* gene founder mutations. *J Natl Cancer Inst* 1999; 91: 2112-2117.
  14. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR. Primary node negative breast cancer in *BRCA1* mutation carriers has a poor outcome. *Ann Oncol* 2000; 11: 307-313.
  15. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A for the Institut Curie Breast Cancer Study Group. Risk of breast recurrence and contralateral breast cancer in relation to *BRCA1* and *BRCA2* mutation status following breast-conserving surgery and radiotherapy. *Eur J Cancer* 2005; 41: 2304-2311.
  16. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivetto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in *BRCA1/2*-associated stage I/II breast cancer. *J Clin Oncol* 2006; 24: 2437-2443.
  17. Joukov V, Groen AC, Prokhorova T, Gerson R, White E, Rodriguez A, Walter JC, Livingston DM. The *BRCA1/BARD1* heterodimer modulates ran-dependent mitotic spindle assembly. *Cell* 2006; 127: 539-552.

## Lidia Larizza

### Medical Genetics, University of Milan, Italy

The study by Byrski et al. (*Breast Cancer Res Treat* 2007 May 10 (Epub)) raises interest for both clinical oncologists and basic science investigators as it provides novel information on the response to neo-adjuvant chemotherapy of breast cancer women carrying a *BRCA1* germ-line mutation. Several studies have reported on different regimens of chemotherapy in women with breast cancer, but the response to therapeutic options has not yet been compared between the sporadic and the hereditary subgroups.

The report by the Polish Hereditary Breast Cancer consortium shows that taxane combined with doxorubicin determines in *BRCA1*-positive patients a decreased response as compared to other DNA-damaging therapies. An increasing number of investigations [for review see 1] have looked at the major role of *BRCA1* as a modulator of chemotherapy-induced DNA damage. In particular preclinical studies have pointed out the interference of damaged *BRCA1* in the response to mitotic spindle poisons. Within these studies it has emerged that intact *BRCA1* protein is required for induction of apoptosis [2], while downregulation of *BRCA1* renders MCF7 cells insensitive to paclitaxel through inactivation of the spindle checkpoint [3]. A variety of experimental models consolidated this evidence [4, 5] and clinical studies investigating the role of *BRCA1* in the response to

chemotherapy were recommended. One investigation showed that loss of *BRCA1* expression may predict shorter time to progression in metastatic breast cancers treated with taxanes; however, no relationship with the clinical tumour response was observed and no genotyping of the *BRCA1* status was performed [6].

The study by Byrski et al. definitely transfers into the clinical set the findings achieved in preclinical systems, offering a provocative turning point which deserves further studies. As the authors underline, caution should be exercised in drawing definite conclusions, which should await a detailed investigation of larger cohorts of patients. The study compares two small sample sets: 44 Polish women carrying a *BRCA1* founder mutation versus 41 age- and hospital-matched breast cancer patients (controls).

However, the two patient panels have been sorted out stepwise from a larger pool of 4316 incident cases of invasive breast cancer which were identified from 1997 at 18 different Polish hospitals. First 3479 patients (80.7%) accepted the invitation to participate in the study, allowing the locally reviewed medical records to be forwarded to the same centre and evaluated for a set of fixed parameters. Pathology reviews and mutation analysis were conducted independently on 3136 and 3472 patients, respectively, and data were then matched. Yet, according to the study design, the received neo-adjuvant chemotherapy was the main factor determining the reduction in the sample and sorting 820 women out.

Of the 3472 patients 198 (5.7%) were found to carry a *BRCA1* mutation and 44 (29.8%) were treated with neo-adjuvant chemotherapy, compared with 23.2% of the mutation-negative patients. For each *BRCA1*-positive case a matched control was selected among those with available clinical information [41] and the two subgroups were compared. The statistical significance of group differences was assessed using the Fisher exact test. Overall, 35 of the 44 *BRCA1* carriers achieved a complete or partial response (80%) compared to 39 of 41 non-carriers (95%;  $p=0.005$ ). Focus on users of taxane-based regimens showed that six of the 15 *BRCA1* carriers who were given docetaxel had a response, compared to 12 of 12 non-carriers ( $p=0.001$ ).

The authors conclude that the expression of the wild-type *BRCA1* protein is necessary for cancer cells to respond to spindle poisons such as docetaxel. Their result that taxanes may not be useful for the treatment of breast cancer in a significant fraction of *BRCA1* carriers is a suggestion which should be validated by independent studies and should be reconciled with studies with different indications. Indeed, contrary to the results of Byrski et al., a small clinical study reported

on the effectiveness of neo-adjuvant chemotherapy in *BRCA1/2* related breast cancer [7], without however providing enough details on the study design.

Benefits deriving from this study regard the prediction of scarce sensitivity to taxane of *BRCA1*-positive patients in order to avoid unnecessary treatment. Although *BRCA1* carriers represent a small subset of breast cancer patients, related family members can easily be identified and appropriate therapy regimens designed also for those with tumours other than breast cancer. The advantages stemming from this study could however be limited if heterogeneity of response exists within *BRCA1* mutation carriers due to polymorphisms in genes involved in taxane transport, oxidative metabolism and the drug target. Ideally the predictive power of *BRCA1* status should be linked to targeted pharmacogenetic screening, so as to enable the best-tolerated and most effective treatment strategies. However, inconsistencies between a few functional polymorphisms and taxane clearance, outcome and toxicity [8] make currently unrealistic pre-treatment genotyping of *BRCA1* patients for such pharmacogenetic markers.

Furthermore, recent data on molecular profiling of docetaxel cytotoxicity in breast cancer cells showing differences according to drug concentration [9] may have clinical implications. These, in turn, would provide a rational approach to lower the therapeutic concentrations of docetaxel-based chemotherapy. Insights from these studies may contribute to optimizing the design of future prospective clinical studies on *BRCA1* carriers for the development of tailored therapeutic approaches. The study by Byrski et al. represents an important achievement in this direction.

## References

1. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. *BRCA1*, a potential predictive biomarker in the treatment of breast cancer. *Oncologist* 2007; 12: 142-150.
2. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of *BRCA1* on the sensitivity to anticancer agents in p53-deficient cells. *Int J Oncol* 2003; 22: 1169-1173.
3. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. *BRCA1* downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. *Cell Cycle* 2006; 5: 1001-1007.
4. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP. *BRCA1* functions as a differential modulator of chemotherapy-induced apoptosis. *Cancer Res* 2003; 63: 6221-6228.
5. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. *BRCA1* expression modulates chemosensitivity of *BRCA1*-defective HCC1937 human breast cancer cells. *Br J Cancer* 2003; 88: 1285-1291.
6. Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, Sonoo H. Loss of *BRCA1* expression may predict shorter

- time-to-progression in metastatic breast cancer patients treated with taxanes. *Anticancer Res* 2006; 26: 695-701.
7. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancer. *J Med Genet* 2002; 39: 608-610.
  8. Marsh S, Mc Leod HL. Pharmacogenetics and oncology treatment for breast cancer. *Expert Opin Pharmacother* 2007; 8: 119-127.
  9. Hernando-Vargas H, Palacios J, Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. *Oncogene* 2007; 26: 2902-2913.

## Cornelis J.M. Lips

### Department of Endocrinology, University Medical Center, Utrecht, the Netherlands

I believe your conclusion of unresponsiveness to neo-adjuvant therapy in women with *BRCA1*-positive breast cancer is most interesting for oncologists and colleagues attending families with this type of cancer.

In my opinion, it demonstrates that cancer development and multistep carcinogenesis are dependent on specific pathways in molecular pathogenesis.

In addition, it is possible that normal *BRCA1* is required for clinical response to mitotic spindle poisons.

Unfortunately, I am an endocrinologist and have seen many patients with MEN 1, MEN 2, VHL etc., but not families with familial breast cancer. So my opinion in this field is limited.

## Niklas Loman, Åke Borg

### Department of Oncology, Lund University, SE-22185 Lund, Sweden, e-mail: [niklas.loman@med.lu.se](mailto:niklas.loman@med.lu.se)

Genetic counselling and *BRCA* testing in breast and breast-ovarian cancer families has become state-of-the-art in clinical medicine in large parts of the world during the last decade. The purpose is risk assessment and identification of high-risk individuals in order to decrease the morbidity and mortality associated with the increased risk of breast, ovarian and possibly other cancers in mutation carriers. In the treatment of women with breast cancer, the individual *BRCA* status may have implications for the choice of different surgical options such as mastectomy instead of breast conserving surgery followed by postoperative radiotherapy, or in performance of prophylactic contralateral mastectomy and oophorectomy. Furthermore, emerging data suggest that *BRCA* status may also have implications for tumour development, genomics and biology, factors that should be considered when selecting the appropriate medical treatment in cases of breast or ovarian cancer.

While displaying different phenotypes, *BRCA1* and *BRCA2*-associated cancer seem to develop through pathways that have important features in common. The typical *BRCA1*-associated breast cancer is a hormone receptor negative, non-HER2-amplified, high-grade ductal carcinoma [1] with an identifiable gene-expression profile [2] and a cytokeratin profile indicating an origin in the basal/myoepithelial layer [3]. The phenotype of *BRCA2*-associated breast cancer is probably less specific [4], but also distinguishable from *BRCA1*-associated and sporadic breast cancer based on the gene expression patterns [2]. In addition, a subgroup of sporadic breast cancer displays similar features as tumours in *BRCA1* mutation carriers [5], indicating that lessons learned from the treatment of *BRCA1*-associated breast cancer may also be appropriate for this group of basal-like breast cancers. Basal-like breast cancers have been shown to respond well to neo-adjuvant chemotherapy including paclitaxel, doxorubicin, 5-FU and cyclophosphamide [6]. However, few clinical studies have been published to describe the sensitivity of *BRCA1*-associated cancers to specific therapeutic measures and possible differences to other cancers, but experimental data as well as some retrospective studies suggest that *BRCA1*-associated breast and ovarian cancer may have an increased sensitivity to DNA-interacting chemotherapy compared with tumours in non-mutation carriers [7-9].

Recently, further data on sensitivity to taxanes in *BRCA1*-associated breast cancer were presented in a retrospective survey of breast cancer cases [10]. Byrski and coworkers studied a set of 44 primary *BRCA1*-positive breast cancer cases that had all been subject to neo-adjuvant chemotherapy. The 44 cases were compared with 41 age-matched controls that were negative for three of the founder mutations that are prevalent in the Polish population (*BRCA1* 5382insC, C61G and 4153delA). No difference in the rate of pathological complete response (pCR) was observed between the two groups, but a clinical response was more frequent in controls than in cases. The inferior response rate among cases seemed to be restricted to the subgroup of patients receiving docetaxel.

As pointed out by the authors, the retrospective study design and small size of the study inevitably lead to difficulties in the interpretation of the data. Nevertheless, the findings are interesting and should encourage design of new studies aiming at exploring this important aspect of breast cancer treatment. Prospective phase-2 studies are ongoing, both in *BRCA1/BRCA2*-associated breast cancer and in "triple negative" breast cancer (correlating with the basal-like phenotype), comparing taxane with carboplatin therapy in the metastatic setting. More clinical evidence is awaited through gene expression profiling of

tumours in large prospective adjuvant and neo-adjuvant phase-3 trials where response has been prospectively assessed. In addition, retrospective *BRCA* testing should be attempted in studies of similar design. The results of these ethically and practically challenging tasks should be evaluated before considering applying *BRCA* status as a predictive factor in the (neo-) adjuvant treatment of early breast cancer.

## References

1. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in *BRCA1* and *BRCA2*. *J Clin Oncol* 2002; 20: 2310-2318.
2. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrl W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G. Gene-expression profiles in hereditary breast cancer. *N Engl J Med* 2001; 344: 539-548.
3. Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to *BRCA1* tumors. *Mod Pathol* 2005; 18: 1321-1328.
4. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP. *BRCA2* mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. *Am J Surg Pathol* 2007; 31: 121-128.
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci USA* 2003; 100: 8418-8423.
6. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res* 2005; 11: 5678-5685.
7. Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD. Impact of germline *BRCA1* mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. *Cancer* 2003; 97: 527-536.
8. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with *BRCA*-associated ovarian carcinoma. *Cancer* 2003; 97: 2187-2195.
9. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancer. *J Med Genet* 2002; 39: 608-610.
10. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].

## Pål Møller

Section of Inherited Cancer, Department of Medical Genetics, Rikshospitalet-Radiumhospitalet Medical Centre, N-0130 Oslo, Norway, e-mail: pmoller@ulrik.uio.no

### Preoperative *BRCA* testing in breast cancer

Testing for *BRCA* mutations is about to become part of the diagnostic procedures to select treatment for breast cancer patients.

In a recent report, Byrski et al. [1] concluded that neo-adjuvant chemotherapy with docetaxel had no effect in *BRCA1* mutation carrying women with breast cancer. This is important, because the prognosis of *BRCA1* induced breast cancer is poor with today's treatment [2], and it is of obvious interest to determine which treatment regimens work and which do not. Docetaxel is probably not effective to treat *BRCA1* breast cancer. Having that knowledge, patients could be subjected to other treatment regimens which may be beneficial, the cost of trying docetaxel could be avoided, and the patients could be relieved from the side effects of docetaxel. Instead of doing a neo-adjuvant trial in each patient, the patients may be tested for *BRCA1* mutations. This is an argument to include *BRCA* mutation testing in the pre-treatment diagnostic procedures to select adjuvant chemotherapy.

An argument for pre-operative *BRCA* testing of breast cancer patients is to determine the surgical procedure. Patients with small tumours are today offered to choose breast conserving treatment, which includes postoperative radiation therapy. *BRCA* mutation carriers have, however, high risk for a contralateral tumour, and may be candidates for contralateral prophylactic mastectomy with reconstruction. If so, radiation treatment of the ipsilateral side should be avoided – surgical treatment should be ablative with the option of bilateral reconstruction. That is, *BRCA* testing should be completed before selecting surgical treatment. Such rapid testing will – for practical purposes – only be available for locally frequent founder mutations. It is no coincidence that Byrski et al.'s report emerges from a population with established rapid tests for founder mutations. In Norway, all professional groups treating breast and ovarian cancer have suggested to the authorities to institute rapid testing for founder *BRCA* mutations for all incident breast or ovarian cancers [3, 4]. In that population, the test panel will identify about 70% of all mutation carriers. It is doable to streamline the test procedure to have the test results within two weeks.

Also, there is an argument to identify *BRCA1* mutation carriers among breast cancer patients, so as to improve the prognosis by oophorectomy [2].

## References

1. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].
2. Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Mæhle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM. Surveillance for familial breast cancer: differences in outcome according to *BRCA* mutation status. *Int J Cancer* 2007; 121: 1017-1020.
3. Moller P, Hagen AI, Apoldm J, et al. Genetic epidemiology of *BRCA* mutation – family history identifies less than 50% of mutation carriers. *Eur J Cancer* [Epub ahead of print].
4. www.inherited-cancer.com. Inherited breast and ovarian cancer. Consensus. Jan 2007.

## Hakan Olsson

Department of Oncology Lund University Hospital,  
The Jubileum Institute, Lund, Sweden

### Tailoring therapy in breast cancer in relation to aetiological factors

Evidence is accumulating that the biology of breast cancer at least partly is related to aetiological factors and the state/origin of the epithelial cell at time of initiation. This has been postulated before in relation to hormonal and genetic risk factors in breast cancer [1-3] and supported by results from gene expression analysis [4-7] and breast cancer stem cell research [8-10]. The alternative hypothesis would suggest that cancer development is a random process affecting a common breast stem cell and that the biology would depend on crucial genes mutated in a random fashion. The age of a tumour would in this setting be more important as tumour progression would increase by the inherent genetic instability and make therapy less successful late in the disease course. The first hypothesis would make tumours more stable during disease course (more dependent on the origin of the tumour cell than the progression) and it would therefore both in the neoadjuvant and in the advanced stage be possible to give a tailored treatment affecting crucial growth factor pathways.

The results by Byrski et al. 2007 [11] looking at neoadjuvant chemotherapy in *BRCA1* carriers in Poland is still another study suggesting the value of tailored therapy in hereditary breast cancer and favouring the first hypothesis, as they found that taxane chemotherapy was less effective as neoadjuvant therapy than other therapy combinations.

In patients with *BRCA1* and *BRCA2* mutations studies are already underway to assess if tailored therapy in the

form of platinum or mitomycin containing chemotherapy or use of PARP inhibitors improve metastatic therapy [12-14]. Case stories and animal models support this approach.

Two questions are pertinent in relation to the recent results: should all breast and ovarian cancer patients be offered *BRCA1/2* testing before therapy is initiated, and in the clinic, should neoadjuvant therapy already be differentiated depending on *BRCA1* mutations?

Except for some populations having very strong *BRCA1/2* founder mutations, so far data indicate that most *BRCA1/2* carriers with breast cancer are identified through family history. In unselected breast cancer populations regardless of age they would account for not more than 1-2% of cases. For ovarian cancer this would be higher, 10-15%, but again most of the patients would be identified through a family history. Therefore it is questionable to test all patients with breast cancer except for situations where family histories would not be present or reliable or if the patient originates from a geographic/ethnic area with very strong founder mutations. However, patients with a strong family history should be offered testing now for two reasons: first to assess the risk for the individual and later the family; secondly a positive mutation test may indeed affect primary therapy and patient recruitment into randomised trials.

Is there a case for offering *BRCA1* patients in the clinic differentiated neoadjuvant therapy? So far studies are retrospective and nonrandomised. The undertaking of a randomised prospective pan-European or worldwide study would be optimal to support clinical care. Unfortunately it might be difficult to achieve enough power within a reasonable time to answer the research question. Outside the scope of such a trial, data indicate for clinicians that regimens containing platinum and mitomycin should be favoured in therapy of *BRCA1* associated breast and ovarian cancer, while taxanes are not a first choice.

Is there an even wider scope of this reasoning? How about tumours similar in phenotype to *BRCA1* tumours (e.g. triple negative breast cancer)? Would these tumours benefit from the same regimens that turn out to be effective in *BRCA1* [15, 16]? Again there is a need for randomised studies to assess this. The timeframe for studying these basal like tumours may be easier as this would constitute a larger group of breast cancer than only *BRCA1* mutation carriers.

However, recent data suggest that the tumour phenotype defined by expression analysis does not consistently predict tumour response in locally advanced tumours [15], again corroborating the fact that there is a need to bring tumour biological data together with aetiological risk factor data such as Byrski et al. has done to find out if therapy prediction could be improved.

## References

1. Olsson H. Reproductive events, occurring in adolescence at the time of development of reproductive organs and at the time of tumour initiation, have a bearing on growth characteristics and reproductive hormone regulation in normal and tumour tissue investigated decades later – a hypothesis. *Med Hypotheses* 1989; 29: 93-97.
2. Olsson H. Tumour biology of a breast cancer at least partly reflects the biology of the tissue/epithelial cell of origin at the time of initiation – a hypothesis. *J Steroid Biochem Mol Biol* 2000; 74: 345-350.
3. Olsson H. A hypothesis about the tumour development and clinical picture in hereditary breast cancer. *Eur J Cancer* 2001; 37: 2023-2029.
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. *Nature* 2000; 406: 747-752.
5. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrl W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G. Gene-expression profiles in hereditary breast cancer. *N Engl J Med* 2001; 344: 539-548.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 2001; 98: 10869-10874.
7. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson H, Meltzer P, Borg A, Trent J. Molecular classification of familial non-*BRCA1/BRCA2* breast cancer. *Proc Natl Acad Sci* 2003; 100: 2532-2537.
8. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Lobbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. *Breast Cancer Res Treat* 2007; Jun 20 [Epub ahead of print].
9. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. *Cell Prolif* 2003; 36 (Suppl 1): 73-84.
10. Wicha MS. Identification of a murine mammary stem cell; implications for studies of mammary development and carcinogenesis. *Breast Cancer Res* 2006; 8: 109.
11. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancer. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].
12. Zhou C, Smith JL, Liu J. Role of *BRCA1* in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective *BRCA1*. *Oncogene* 2003; 22: 2396-2404.
13. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of *BRCA* tumours. *Curr Opin Pharmacol* 2005; 5: 338-393.
14. Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin (CDPP) in "triple-negative" breast cancer. Abstract of the San Antonio Breast Cancer Symposium, San Antonio 2006.
15. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res* 2007; 13: 2329-2334.
16. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, Anker G, Akslen LA, Botstein D, Børresen-Dale AL, Lønning PE. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. *Mol Cancer Ther* 2006; 5: 2914-2918.

## Jae-Gahb Park

Department of Surgery, Seoul National University Hospital, Seoul, Korea

I do agree with Jan and Rodney that because we have good in vitro and matched observational studies which suggest inborn resistance to taxane in the mutational group, I am also with you that we could suggest the idea that in the mutation carrier group in breast cancer taxane should be avoided and appropriate choice of chemotherapy would be very important.

Second, for the screening of *BRCA1* in general patients, it might be considerable, but because the incidence will be too low and some cost and benefit issues should be considered as well, my opinion is that we have to select, for example, in addition to those familial candidates, younger patients with little response to taxane, or triple negative cases, etc.

## Sinisa Radulović, Mira Branković-Magić

Institute for Oncology and Radiology of Serbia, Belgrade, Serbia and Montenegro

### Is the *BRCA1* gene a useful predictive marker for (neo-adjuvant) chemotherapy choice in breast cancer?

In the recent issue of Breast Cancer Research and Treatment Journal members of the Polish Hereditary Breast Cancer Consortium published an interesting article concerning the response to neoadjuvant chemotherapy in *BRCA1* germ-line mutation carriers [1]. They identified 44 Polish women with a *BRCA1* mutation who had been treated with neo-adjuvant chemotherapy. Response rate (by their criteria, i.e. complete disappearance or any decrease in size of the tumour) was found to be lower in *BRCA1* mutation carriers (80%) in comparison to the response rate of matched mutation-negative breast cancer controls (95%). Interestingly, only 6 out of 15 *BRCA1* carriers obtained responses to a chemotherapy regimen containing docetaxel compared to a 100% response rate in 20 *BRCA1* carriers receiving chemotherapy without docetaxel. Nine women with *BRCA1* mutations

did not achieve tumour response to docetaxel-containing chemotherapy.

The majority of non-carriers responded to neo-adjuvant chemotherapy, 12 out of 12 to docetaxel-containing and 27 out of 29 to non-docetaxel regimens. The authors concluded that *BRCA1* mutation carriers frequently lack sensitivity to docetaxel in the neo-adjuvant setting and that functional *BRCA1* is required for the tumour shrinkage to spindle poisons.

Neo-adjuvant chemotherapy is increasingly being used for treatment of early-stage and locally advanced breast cancer. The theory behind this is to decrease the size of the tumour, allowing breast conserving surgery, to look *in-vivo* at the drug sensitivity, and to use active systemic treatment of micrometastasis, achieving longer disease-free and overall survival. Clearly, neo-adjuvant chemotherapy increases the frequency of breast conserving surgery but does not prolong overall survival compared with adjuvant chemotherapy. However, patients achieving pathologic complete response have significantly prolonged disease-free and overall survival after neo-adjuvant chemotherapy [2]. Today, pathologic complete response is considered to be a surrogate marker for favourable prognosis of neo-adjuvant chemotherapy, but it is achieved only in 3-30% of patients [3]. Pathologic complete response has recently been defined as no invasive or noninvasive tumours in the breast and axillary tissue removed at the time of surgery [4]. In the article by Byrski and colleagues pathologic complete responses were achieved in 4 of 44 (9.1%) *BRCA1* mutation carriers and in 2 of 41 (4.9%) non-carriers. They stated that residual tumours were not identified in the breast tissue but the status of the axillary nodes was not mentioned. Interestingly, no single patient, regardless of *BRCA1* mutation status, achieved (pathologic) complete response to docetaxel (total number of 27 patients), i.e. all 6 complete responders received FAC (5 patients) or AC regimen (1 patient). This is in contrast to NSABP B-27 results, where pathologic response was 19% in the combinational chemotherapy plus docetaxel compared with 9% in the combinational (AC) therapy arm alone [5]. However, increased pathologic complete response with more effective drugs, such as docetaxel, has not led to consistent improvement in survival.

So, what are the factors that might affect sensitivity to neo-adjuvant chemotherapy? There are some identified predictive factors associated with pathologic complete response such as hormone receptor status (response significantly higher in hormone receptor-negative tumours), pathologic characteristics (invasive lobular carcinoma are less likely to achieve response compared to invasive ductal carcinoma, and poor differentiation, high nuclear grade and high

proliferation index are predictors for the response to chemotherapy) and, finally, status (amplification) of HER2 could predict response to chemotherapy plus trastuzumab. In the article by Byrski and colleagues, lobular carcinoma was diagnosed in 2.3% and 14.6% of patients with and without *BRCA1* mutations, respectively. Oestrogen receptor negativity was twice as frequent in the *BRCA1* carrier group (90.9%) compared with the non-carrier group (43.9%). The situation is similar for progesterone receptor negativity. Higher incidence of HER2 positive tumours in the control group (26.8%) than in *BRCA1* carriers (18.2%) was observed. All of these parameters should be taken into consideration when analysing the results of the Polish Hereditary Breast Cancer Consortium data.

Finally, many studies have been done by using DNA microarrays and expression of large numbers of genes in order to find groups of genes that might be associated with drug sensitivity in neo-adjuvant chemotherapy. None of them, although most of these studies are on an insufficient number of patients, was able to identify any gene(s) as a predictive factor for drug sensitivity. Is *BRCA1* one of them, at least in relation to docetaxel chemotherapy?

The role of *BRCA1* in the cellular response to chemotherapy has been reviewed [6]. The major role for *BRCA1* is to respond to DNA damage by participating in cellular pathways for DNA repair, mRNA transcription, cell cycle regulation, and protein ubiquitination. Although the *BRCA1* gene is a DNA damage response gene, it also appears to play a role in the regulation of mitotic process and, in such way, *BRCA1* is involved in the response to docetaxel and paclitaxel. Binding of *BRCA1* to  $\gamma$ -tubulin is involved in the correct segregation of chromosomes during mitosis [7]. Mutation of exon 11 of *BRCA1* leads to chromosomal instability, i.e. intact *BRCA1* participates in the deflection of abnormal mitosis and in the induction of apoptosis to prevent the replication of aneuploid cells [8]. An additional mechanism by which *BRCA1* participates in sensitivity to spindle poisons may involve the c-jun N-terminal kinase (JNK) pathway, which is specifically activated after treatment with paclitaxel. The loss of *BRCA1* expression results in decreased JNK activation after paclitaxel treatment [9].

Preclinical studies indicated that *BRCA1* is required for paclitaxel sensitivity in breast cancer cell lines. Two groups [10, 11] reported significant increase to spindle poison (paclitaxel and vinorelbine) when functional *BRCA1* was reconstituted into the HCC1937 cells. However, decreased paclitaxel sensitivity was reported when *BRCA1* was expressed in the *BRCA1*-mutant SNU-251 human ovarian cell line [12]. Overall, *BRCA1* is required for the induction of apoptosis in response to



spindle poison (just to mention here that paclitaxel and docetaxel have not exactly the same mechanism of action), particularly in breast cancer cells.

The role of the *BRCA1* gene in response to spindle poisons in clinical studies has been less characterised. Some findings are in a disagreement with preclinical studies. Egawa et al. [13] demonstrated that lower expression of *BRCA1* mRNA is associated with increased sensitivity to docetaxel. What is clear from the clinical data, *BRCA1* inactivation through mutation confers sensitivity to DNA-damaging drugs. In the article by Byrski et al. mutation carriers not responding to docetaxel also received doxorubicin, which is a DNA-damaging agent. Is it possible that docetaxel “protects” tumour cells from cytotoxic action of doxorubicin? Obviously, the use of a single agent would allow much better understanding of *BRCA1* mutation and response to a particular drug.

The obtained data indicate that patients who need neoadjuvant treatment with docetaxel regimens have to be tested for the presence of *BRCA1* mutation. *BRCA1* mutation presence is a rare event in sporadic breast cancer and the “gold standard” for *BRCA1* testing still implies sequencing of the entire coding region of the gene. It seems that *BRCA1* testing for neoadjuvant chemotherapy may be necessary, but in practice cannot be performed in all countries, especially in countries where “founder” mutations have not been detected or their proportion is small.

As the authors pointed out, their study is observational and not conclusive, but the work is interesting and intriguing enough to facilitate further clinical prospective studies investigating the role of *BRCA1* mutations in the response to chemotherapy.

## References

- Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancer. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].
- Wolmark N, Wang J, Momounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. *J Natl Cancer Inst Monogr* 2001; 30: 96-102.
- Portera CC, Swian SM. Neoadjuvant Chemotherapy: a Step Closer to Individualized Therapy. *ASCO Educational Book* 2007: 51-55.
- Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. *J Clin Oncol* 2006; 24: 1940-1949.
- Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 2006; 24: 2019-2027.
- Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of *BRCA1* in the cellular response to chemotherapy. *J Natl Cancer Inst* 2004; 96: 1659-1668.
- Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in *BRCA1* exon 11 isoform-deficient cells. *Mol Cell* 1999; 3: 389-395.
- Hsu LC, Doan TP, White RL. Identification of a gamma-tubulin-binding domain in *BRCA1*. *Cancer Res* 2001; 61: 7713-7718.
- Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of *BRCA1* leads to increased chemoresistance to microtubule-interfering agents, all effect that involves the JNK pathway. *Oncogene* 2001; 20: 6597-6606.
- Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP. *BRCA1* functions as a differential modulator of chemotherapy induced apoptosis. *Cancer Res* 2003; 63: 6221-6228.
- Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. *BRCA1* expression modulates chemosensitivity of *BRCA1*-defective HCC1937 human breast cancer cells. *Br J Cancer* 2003; 88: 1285-1291.
- Zhou C, Smith JL, Liu J. Role of *BRCA1* in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective *BRCA1*. *Onogene* 2003; 22: 2396-2404.
- Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Decreased expression of *BRCA2* mRNA predicts favorable response to docetaxel in breast cancer. *Int J Cancer* 2001; 95: 255-259.

## Thangarajan Rajkumar

Department of Molecular Oncology Cancer Institute (WIA), Adyar, India

I have gone through the paper and feel it is valid to offer *BRCA1* testing if the patient is planned for taxanes. In our own group of patients, which at present is small, we have not yet had use of taxanes as neoadjuvant therapy. In our Institution, we plan for concurrent chemo and radiotherapy, either with CMF or FAC, for locally advanced breast cancers.

## Evangelia Razis<sup>1</sup>, Drakoulis Yannoukakos<sup>2</sup>

<sup>1</sup>Diagnostic and Therapeutic Centre of Athens HYGEIA, Athens, Greece

<sup>2</sup>Molecular Diagnostics Laboratory, IRRP, National Centre for Scientific Research “Demokritos”, Athens, Greece

### Docetaxel (in)sensitivity in *BRCA1*-positive breast cancers?

In a recent article in the *New England Journal of Medicine* [1], it was shown that, despite what was

previously believed, *BRCA1* gene mutation carriers do not carry a worse prognosis than other breast cancer patients. However, there is a mounting body of evidence indicating that *BRCA1* mutations may affect sensitivity to specific chemotherapy agents.

The *BRCA1* gene is mutated in approximately 5% of breast cancers but is also under-expressed in several sporadic cancers. The *BRCA1* gene, located on chromosome 17, encodes a 220-kDa protein that is responsible for DNA damage repair, cell cycle regulation, mRNA transcription and protein ubiquitination [2]. *BRCA1* is phosphorylated by the ataxia-telangiectasia mutated (ATM) protein in response to DNA damage. Many chemotherapeutic agents act by causing direct DNA damage via interstrand cross-links (alkylators, anthracyclines), DNA adducts (platinum agents) and double strand breaks (bleomycin). *BRCA1* activation is part of the DNA repair process. In sporadic cancers with low levels of *BRCA1* expression, there is little proof of differential sensitivity to chemotherapy agents [3]. However, in *BRCA1* loss, both preclinical and clinical studies have shown that response to DNA damaging agents is increased [4, 5].

Another class of antineoplastic agents is the microtubule poisons. Those act by either blocking or promoting the depolymerization of the microtubules in the mitotic spindle, leading to apoptosis. Spindle-poison-induced apoptosis is regulated by the c-jun N-terminal kinase (JNK) pathway [6]. *BRCA1* is also involved in the regulation of mitosis through the JNK pathway and its increased expression has been shown to induce apoptosis caused by microtubule poisons. Thus *BRCA1* mutation carriers are bound to be less sensitive to taxanes, the latter being microtubule poisons.

In the study by Byrski et al. [7] the response of 44 *BRCA1* mutation carriers with breast cancer to neoadjuvant therapy was compared to that of 41 age- and hospital-matched controls. The response of non-carriers was higher than that of carriers, and within the hereditary group, docetaxel treated patients did significantly worse than those that did not receive docetaxel. Within the non-carrier group there was no difference in response according to the use of docetaxel. Non-taxane based regimens included FAC, AC, CMF and CMFP, whereas docetaxel was given always in combination with doxorubicin. It is thus impossible to "tease out" the effect of *BRCA1* on doxorubicin sensitivity from that on docetaxel sensitivity. Furthermore, the numbers of patients in each subgroup are too small to yield strong results.

Other authors have attempted to look at the effect of *BRCA1* on taxane efficacy. On cell lines this has been tested repeatedly, always yielding the same result: namely, that the loss of *BRCA1* function leads to taxane

resistance [8, 9]. In the clinic, a Japanese study showed that time to disease progression after treatment with taxanes was shorter for *BRCA1* mutation carriers than for non-carriers [10]. Egawa et al. on the other hand found that increased *BRCA1* mRNA expression led to increased response to docetaxel [3].

More evidence is provided by studies regarding the chemosensitivity of triple negative or basal-like cancers. *BRCA1* related cancers are frequently triple negative. Triple negative cancers responded particularly well to neoadjuvant paclitaxel-FAC in a study by Rouzier et al. [11]. However, as noted in the study by Byrski et al., not all triple negative cancers are *BRCA1* mutant. Additionally, at this point *BRCA1* patients' sensitivity to taxanes appears to be more related to the absence of the *BRCA1* promoting effect on the microtubule checkpoint than to the absence of hormone receptors.

Though the results of the study by Byrski et al. are consistent with the theoretical models, preclinical and clinical studies, they have to be approached with caution because the study is not prospective and the number of patients is small. Finally, the confounding variable of several different regimens and different agents (with variable efficacy in *BRCA1* patients) may cloud the issue further. However, there is at this point so much corroborative evidence regarding the effect of *BRCA1* on chemotherapy efficacy that the need for prospective studies in this field is imperative.

## References

1. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. Clinical outcomes of breast cancer in carriers of *BRCA1* and *BRCA2* mutations. *N Engl J Med* 2007; 357: 115-123.
2. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of *BRCA1* in the cellular response to chemotherapy. *J Natl Cancer Inst* 2004; 96: 1659-1668.
3. Egawa C, Motomura K, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Inaji H, Koyama H, Noguchi S. Increased expression of *BRCA1* mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. *Breast Cancer Res Treat* 2003; 78: 45-50.
4. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancer. *J Med Genet* 2002; 39: 608-610.
5. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP. *BRCA1* functions as a differential modulator of chemotherapy-induced apoptosis. *Cancer Res* 2003; 63: 6221-6228.
6. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of *BRCA1* leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. *Oncogene* 2001; 20: 6597-6606.
7. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Swiec M, Wisniewski R, Siolek M, Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium.

- Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers. *Breast Cancer Res Treat.* 2007; May 10 [Epub ahead of print].
8. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. *Cancer Sci* 2006; 97: 813-820.
  9. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. *BRCA1* expression modulates chemosensitivity of *BRCA1*-defective HCC1937 human breast cancer cells. *Br J Cancer* 2003; 88: 1285-1291.
  10. Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, Sonoo H. Loss of *BRCA1* expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. *Anticancer Res* 2006; 26: 695-701.
  11. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Puzstai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res* 2005; 11: 5678-5685.

## Fernando Schmitt

**Medical Faculty of Porto University and Institute of Molecular Pathology and Immunology of Porto University (IPATIMUP), Porto, Portugal**

### Is *BRCA1* a possible predictor of response to neo-adjuvant chemotherapy?

*BRCA1* is an important gene of breast cancer susceptibility [1]. Germinal mutations in this gene are responsible for 5% of all breast cancer cases and the tumours that arise in this setting share some special histological characteristics such as high grade, pushing margins, ER and HER2 negativity, frequently P53 mutations and basal phenotype. The normal *BRCA1* functions are related to DNA repair and cell cycle control and recently it was demonstrated that the *BRCA1* status can predict response to chemotherapy [2]. Recently, Byrski et al. [3] showed that cases of breast cancer in *BRCA1* mutation carriers had a lower response to docetaxel when compared with non-carriers (80 vs. 95%) and these authors conclude that breast cancers among *BRCA1* carriers frequently do not exhibit sensitivity to taxanes (docetaxel) in the neoadjuvant setting. *BRCA1* may increase cell sensitivity to spindle poisons by signalling a pro-apoptotic pathway in response to spindle damage. In the absence of functional *BRCA1*, the mitotic spindle checkpoint is not activated and apoptosis is not induced. However, as recognized by the authors this study is an observational study, with a small number of patients and without a standard protocol. Patients also received other different drugs, such as doxorubicin, which is a DNA-damaging drug, and in this case a lack of functional *BRCA1* and P53 (frequently mutated in these patients) genes leads to better response to treatment. So, to clarify the role of taxanes in *BRCA1* mutated patients

still requires a large, randomized and prospective study.

However, two important questions should be highlighted concerning *BRCA1* and chemotherapy. First, there is no doubt that there is much evidence showing that *BRCA1* can be a good predictor of response to chemotherapy, not only resistance but also sensitivity. Rosell et al. [4] showed that low levels of *BRCA1* mRNA significantly increased survival in gemcitabine/cisplatin-treated patients. Recently, a high clinical response to anthracyclines in *BRCA1* carriers with breast cancer was demonstrated [5]. This drug inhibits topoisomerase 2 $\alpha$ , leading to interruption of DNA replication and damage to the double helix that cannot be repaired in *BRCA1* deficient cells. There is also evidence that medullary breast carcinomas are chemosensitive for some drugs and we know that MBC are frequent in *BRCA1* carriers [6].

Is it time to offer each woman with a newly diagnosed breast cancer the option of *BRCA1* testing? I am not sure. First, there are established clinical and pathological criteria to raise the suspicion of hereditary breast cancer and of course these cases should be investigated. Second, there is evidence that *BRCA1* can be deficient in some non-hereditary cancers by mechanisms other than mutations. In basal-like breast carcinomas (high grade breast carcinomas, ER and HER2 negative and positive for a basal marker) [7] *BRCA1* inactivation by methylation or by over-expression of inhibitors like ID4 [8] was demonstrated. Probably these cases also have benefits using specific chemotherapy and the analysis of mutations will be negative. However, it is important to stress that not only for *BRCA1* but also for other genes, like P53, chemotherapy in breast cancer will be guided according to specific gene alterations. In fact, recently Rottenberg et al. [9] studying the responses of spontaneous *BRCA1* and P53-deficient mammary tumours arising in conditional mouse mutations to doxorubicin, docetaxel and cisplatin showed that the response of individual cases varies, but eventually all become resistant to the maximum tolerable dose of doxorubicin or docetaxel but still respond well to cisplatin even after multiple treatments in recurrences.

## References

1. Foulkes WD. *BRCA1* functions as a breast stem cell regulator. *J Med Genet* 2004; 41: 1-5.
2. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of *BRCA1* in the cellular response to chemotherapy. *J Natl Cancer Inst* 2004; 96: 1659-1668.
3. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers. *Br Cancer Res Treat* 2007; [Epub ahead of print].
4. Rosell R, Cobo M, Isla D, Camps C, Massuti B. Pharmacogenomics and gemcitabine. *Ann Oncol* 2006; 17 (Suppl 5): v13-v16.
5. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. *BRCA1*,

- a potential predictive biomarker in the treatment of breast cancer. *Oncologist* 2007; 12: 142-150.
6. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. *Br Cancer Res* 2007; [Epub ahead of print].
  7. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. *Virchows Arch* 2005; 447: 688-694.
  8. Turner NC, Reis-Filho JS, Russel AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, et al. *BRCA1* dysfunction in sporadic basal like breast carcinoma. *Oncogene* 2007; 26: 2126-2132.
  9. Rottenberg S, Nygren AOH, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumours in a conditional mouse model for hereditary breast cancer. *Proc Natl Acad Sci USA* 2007; 104: 12117-12122.

## Rita Schmutzler

**Stiftungsprofessorin der Deutschen Krebshilfe, Abt. Molekulare Gynäko-Onkologie Universitäts-Frauenklinik zu Köln, e-mail: rita.schmutzler@uni-koeln.de**

Thank you very much for calling my attention to your interesting article that provides the basis for the initiation of RCTs to compare taxane-based versus platin-based neo-adjuvant regimens.

Although we do not have data on neo-adjuvant therapy we have seen a very dramatic response (complete remission!) of an extensive local relapse (chest wall recurrence with multiple axillary lymph nodes combined with a severe oedema of the whole arm) in a *BRCA1* mutation carrier when administering carboplatin second line after taxane mono first line was terminated because of progressive disease.

## Peter D. Simmonds<sup>1</sup>, Diana Eccles<sup>2</sup>

<sup>1</sup>Consultant in Medical Oncology, Southampton University Hospitals NHS Trust, Southampton, Hampshire, United Kingdom

<sup>2</sup>Wessex Clinical Genetics Service, Southampton University Hospitals NHS Trust, Southampton, Hampshire, United Kingdom

We read with interest the paper of Byrski et al. outlining their observations of differential responses to neoadjuvant taxane containing chemotherapy in breast cancer cases arising in *BRCA1* gene carriers and non-carriers. The question of how *BRCA1* and *BRCA2* mutation status might influence the response to treatment is of great interest clinically and the findings presented are in line with what might be expected from the

published data from *in vitro* experiments in *BRCA1* and *BRCA2* null cell lines. However, although interesting, the data presented are not sufficiently robust to alter current clinical management in *BRCA1* gene carriers.

Breast cancer cases were all in younger women and gene carrier ages were matched with non-carrier ages. Only the Polish founder mutations have been identified; presumably cases did not have full *BRCA1* and *BRCA2* mutation testing so that there are plausibly a number of gene carriers represented within the "non-carriers". This is particularly true as 41.5% of the "non-carriers" had a family history (presumably of breast cancer) and 36.5% of these same "non-carriers" had missing family history data.

The response to neoadjuvant chemotherapy was obtained from chart review (it is not clear whether the genetic status of the patients was known to the clinician extracting the information from the case notes) and pathology assessment. Comparison between clinical assessment of tumour size at presentation and pathological assessment of size at completion of chemotherapy is problematic. Using two different methods of assessment has inherent inaccuracies.

Imaging assessment generally includes invasive and non-invasive components of the tumour. It is unclear what is included in the pathological assessment of tumour size but if it is invasive tumour only, tumours that have a significant component of non-invasive tumour will appear to shrink less than those which are predominantly invasive tumour (perhaps more likely in *BRCA1* associated tumours). Clinical assessment of axillary lymph node involvement is unreliable. It is not clear that all patients that were classified as node positive preoperatively had cytological confirmation.

The vast majority of breast cancers in both carriers and non-carriers seem to have had a partial response to any neoadjuvant chemotherapy and all patients who received docetaxel also received doxorubicin, which would be anticipated to be effective in *BRCA1* mutation carriers. Patients were only matched for centre, age at diagnosis and year of birth. There was no attempt to match for other important determinants of prognosis such as tumour size, grade (no information has been given about tumour grade), ER status, Her2 status, or nodal status. There are important imbalances in some of these prognostic factors between the groups.

Finally, since no significant difference in mortality was observed between the groups, it would be premature to use these data to recommend a change in treatment. However, a well designed prospective randomised trial comparing two neoadjuvant treatment regimens with and without docetaxel would be an option to explore this observation further. A population with well recognised founder mutations in *BRCA1* would be ideal as early and

rapid genetic testing can be offered in such a population at the time of diagnosis, and cases matched for all major prognostic tumour factors but highly unlikely to be gene carriers (founder mutations excluded and no significant family history) would allow a better assessment of the role of *BRCA1* mutation status in independently influencing the outcome of treatment.

**Jacob Smeltzer, Peter T. Silberstein<sup>1</sup>,  
Henry Lynch<sup>2</sup>**

**<sup>1</sup>Creighton University Division of Hematology/Oncology,  
Omaha, USA**

**<sup>2</sup>Department of Preventive Medicine and Public Health,  
Creighton University, Omaha, USA**

#### **Personalized chemotherapy for *BRCA1* mutation-positive patients**

Why should we treat all hereditary breast cancer (HBC) syndrome affected patients as if they were clinically, genetically, and pathogenically the same disease? Byrski et al. [1], in recognizing the etiologic, pathologic, and clinical variability of selected breast cancer cases, provide preliminary evidence that *BRCA1* patients are less responsive to taxane-based therapy when compared with their *BRCA2* and sporadic breast cancer counterparts. This is a reasonable supposition in that there is voluminous evidence supporting the hypothesis that breast cancer shows marked differences in sporadic and in the several hereditary varieties of this disease. Hence, it should not be surprising that hereditary cases may differ in response to therapy. For example, *BRCA1* HBC frequently harbors a distinctive pathology phenotype, consisting of an increased number of aneuploid cancers, more medullary carcinomas, and high proliferation rates as measured by DNA flow cytometry and mitotic grade, with less ductal carcinoma *in situ* (DCIS) than in non-familial cases [2-4]. The high S-phase fraction has been attributed to a *BRCA1*-linked subset, which is in accord with the suggestion that the *BRCA1* mutation is predisposed to enhanced cellular proliferation [5].

This model for the *BRCA1* phenotype considers the tumors to be in an advanced state of genetic evolution [2]. In contrast, the "other" HBCs with *BRCA2* mutations with 15q linkage appear to lack the high-grade, aneuploidy, and high proliferation of *BRCA1* HBCs; in addition, they are not deficient in *in situ* carcinoma [2, 3]. This "other" group also has more invasive, lobular, tubular-lobular, and cribriform histologies, and when pathologically aggregated they fit mutation-confirmed *BRCA2* HBC cases and appear more like breast cancer occurrence in the general population [4]. Yet to be

explored are the histopathology and clinical features in a litany of other HBC-prone syndromes such as breast cancer patients with Li-Fraumeni syndrome (*p53* germline mutation), Peutz-Jeghers syndrome (*STK11* mutation), and the *CHEK2* mutation, which is believed to be the most common breast-cancer predisposing mutation to have been discovered since the *BRCA* mutations' identification in the mid-1990s [6, 7].

*BRCA1* is a key tumor suppressor gene, and mutations in it markedly increase the risk of breast and ovarian cancer. Functionally, this gene is an integral component in recognizing and repairing double-stranded DNA damage, upregulates *p53*, and mediates nucleotide excision repair [8]. It also has a significant role in cellular microtubule damage. Understanding the molecular function of *BRCA1* will help to predict response to different chemotherapies that are modulated by *BRCA1* interaction with the drug's mechanism of action.

As *BRCA1* is key to repairing double-stranded breaks in an error-free fashion, hereditary deficiency in *BRCA1* leaves cells particularly vulnerable to DNA damage. Alkylating agents, platinum agents, anthracyclines and topoisomerase inhibitors, which are drugs that facilitate double-stranded breaks, are more potent in *BRCA1* deficient cells than wild-type cells by taking advantage of the cells' increased vulnerability. [8]. Cancer cells that are resistant to cisplatin have been shown to be overexpressing *BRCA1* and have increased *BRCA1*-dependent DNA repair [9]. Furthermore, inhibition of *BRCA1* by antisense RNA leads to a corresponding increase in cisplatin sensitivity [10].

Understanding *BRCA1* function can help us understand which chemotherapies will be effective in killing cancer cells as well as those to which the cancer cells will most likely have resistance. *BRCA1* has a role in sensing microtubule damage and, through the Jun N-terminal kinase (JNK) pathway, facilitating cell cycle arrest. Unlike its role with DNA-damaging chemotherapies, *BRCA1* deficiency leads to resistance to microtubule chemotherapies [8]. Complementing this knowledge, cell lines resistant to the taxane drug paclitaxel, which acts on the microtubules, have then been reconstituted to wild-type *BRCA1* and had a 1000-fold increase in sensitivity [11].

The limited retrospective neoadjuvant chemotherapy studies show that *BRCA1* mutation carriers have greater clinical response and are more chemosensitive than wild types. In the Chappius study, 10/11 *BRCA1/2* mutation carriers vs. 2/11 noncarriers had complete clinical response to neoadjuvant therapy for breast cancer [12]. Delaloge found a 100% clinical response in *BRCA1* patients, an 80% response in *BRCA2* patients, and 63% in noncarriers in the neoadjuvant setting, as well

as a significantly higher rate of pathological complete response in *BRCA1* patients [13]. Both studies used DNA double-strand-damaging anthracycline-based chemotherapies and found greater clinical sensitivity in *BRCA1* patients.

Ovarian cancer patients with *BRCA1* mutations show increased sensitivity to the platinum DNA damaging agents similar to that exhibited by breast cancer *BRCA1* cells [8]. Husain showed that antisense inhibition of *BRCA1* restored cisplatin chemosensitivity in ovarian cancer cell lines that were previously resistant to cisplatin [9]. Cass compared the survival rate of Jewish ovarian cancer patients who had *BRCA1* mutations, *BRCA2* mutations, and no mutations. The median survival of the *BRCA* patients was higher than those without mutations. Eighty-six percent of the *BRCA* heterozygotes responded to chemotherapy while only 41% of the sporadic patients responded ( $p=0.01$ ). All patients were treated with carboplatin, and the majority received that drug in combination with paclitaxel [14].

Rennert recently showed that the prognosis may be similar for *BRCA1* patients and sporadic breast cancer patients [15]. However, in previous studies *BRCA1* status was a negative predictor of prognosis. Specifically, in the subset of patients not receiving adjuvant chemotherapy, *BRCA1* patients had worse overall survival than non-carriers [16]. In Rennert's study, *BRCA1* patients receiving chemotherapy had improved overall survival compared to non-*BRCA1* breast cancer patients [15]. The use of chemotherapy appears to be of particular importance to the survival of *BRCA1* patients.

Can we learn about a differential response to chemotherapy by studying other hereditary cancer-prone disorders, such as the Lynch syndrome? Boland [17] has recently reviewed the relationship between 5-fluorouracil (5-FU) and its response to microsatellite instability positivity ( $MSI^+$ ). Even the long-known fact that a DNA mismatch repair (MMR) system is involved "...in signaling a cell death response after sufficiently toxic DNA damage, and that DNA MMR-deficient cells are relatively tolerant to DNA damage [18, 19]. It was subsequently found that this is also true for CRC cells, and that restoration of the MMR system would restore sensitivity to several compounds that damage DNA [20, 21], including chemotherapeutic agents such as fluorouracil (FU) [22]. Thus, the prediction was made that patients with  $MSI^+$  CRCs would be relatively resistant to the beneficial effects of FU-based regimens." [17].

Lynch et al. [23], in evaluating the role of chemotherapy, particularly FU, noted that it is important to make the distinction between those CRC affecteds with  $MSI^+$  vs. those that are microsatellite stable (MSS). Ribic, in a large, prospective, randomized study of chemotherapy, demonstrated that 5-FU was a benefit to patients with CRCs

that were MSS, but a modest 2-fold hazard ratio for death was found among those patients who received 5-FU if their tumor was  $MSI^+$  [24]. In reviewing this subject, Lynch et al. suggest that "The issue of survival will confound studies that are not prospectively randomized and stratified for  $MSI$  status. Nonetheless, a failure to demonstrate survival benefits after adjuvant chemotherapy in patients with  $MSI^+$  tumors or with Lynch syndrome has been demonstrated by most subsequent investigators [25-28]" [23].

Fallik et al. [29] showed that  $MSI^+$  tumors with metastatic colorectal cancer had a better response to the topoisomerase I inhibitor, irinotecan. Based on this study, Lynch et al. have stated that "...it is reasonable to consider the planning of future clinical trials in which non-5FU-based chemotherapy will be used in the adjuvant setting for patients with Lynch syndrome, as well as for other patients with advanced  $MSI^+$  cancers. Also, as there are important biological differences between Lynch syndrome tumors and sporadic  $MSI^+$  tumors (which are caused by epigenetic silencing of *MLH1* and other tumor suppressor genes), these groups may need to be considered separately" [23].

The recent article by Byrski et al. [1] clinically correlates well with the understanding of *BRCA1* functionality in breast cancer patients undergoing neoadjuvant chemotherapy. While the numbers are small, *BRCA1* patients demonstrated particular resistance to the microtubule chemotherapy, docetaxel. Only 6/15 *BRCA1* patients were responsive to docetaxel vs. 12/12 noncarriers, highlighting the specific resistance of *BRCA1* patients to docetaxel. Regardless of ER/PR or Her-2 Neu status, *BRCA1* status appears to be an independent negative predictor of response to taxane chemotherapy [1]. Given the success of taxane chemotherapies in breast cancer, this knowledge of resistance to taxane in breast cancer patients carrying *BRCA1* mutations is particularly important. *BRCA1* patients responded better to Adriamycin than non-*BRCA1* patients and the *BRCA1* patients had a greater complete response (4/19 vs. 2/18) and fewer non-responses (0/19 vs. 2/18) than the non-*BRCA1* patients [1]. Though not analyzed in the paper for significance, this appears to fit with the previously suggested role of *BRCA1* as a marker for sensitivity to DNA damaging chemotherapies.

Boyd analyzed the Sloan-Kettering's and Gynecological Oncology Group's ovarian cancer patients and found that patients with *BRCA* mutations lived longer than non-hereditary patients. The *BRCA* patients did not have a higher response rate to chemotherapy but had a longer disease-free survival than the non-hereditary patients [30]. They evaluated patients in the GOG Trial #111 who were given cisplatin in addition to either cyclophosphamide or paclitaxel. They did not report on the differential response

to paclitaxel/cyclophosphamide in patients with *BRCA1*. The preclinical data and Byrski's report would suggest that the *BRCA1* patients might respond poorly to paclitaxel. This might be an area of future investigation.

Given that *BRCA1* acts by repairing double-stranded DNA damage, preclinical as well as *in vivo* reports such as the recent report by Byrski suggest that *BRCA1* patients should respond well to anthracyclines, platinum, alkylating agents, and less well to taxanes. Simon recently has shown that response to gemcitabine may be related to the level of ribonucleotide reductase subunit 1 (RRM1), and excision repair cross-complementing group 1 gene (*ERCC1*) may predict response to platinum in patients with lung cancer [31]. A *BRCA1* mutation may similarly predict response to different chemotherapy agents. *BRCA1* importance may be beyond its well-established role with hereditary cancer. Given our understanding of its functional role and clinical experience, *BRCA1* status potentially could be considered in the future as a marker to help target effective chemotherapy.

## References

- Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Narod SA, Lubinski J; the Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancers. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].
- Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT. Hereditary breast cancer: pathobiology, prognosis, and *BRCA1* and *BRCA2* gene linkage. *Cancer* 1996; 77: 697-709.
- Marcus JN, Page DL, Watson P, Narod SA, Lenoir GM, Lynch HT. *BRCA1* and *BRCA2* hereditary breast carcinoma phenotypes. *Cancer* 1997; 80 (Suppl): 543-556.
- Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT. *BRCA2* hereditary breast cancer pathophenotype. *Breast Cancer Res Treat* 1997; 44: 275-277.
- Marcus JN, Watson P, Page DL, Lynch HT. Pathology and heredity of breast cancer in younger women. *J Natl Cancer Inst Monogr* 1994; 16: 23-34.
- Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Tjon A Fat G, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Moslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M. The *CHEK2* 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. *Am J Hum Genet* 2003; 72: 1308-1314.
- Kilpivarra O, Vahteristo P, Falck J, Syrjäkoski K, Eerola H, Easton D, Bartkova J, Lukas J, Aittomäki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H. *CHEK2* variant in 1157T may be associated with increased breast cancer risk. *Int J Cancer* 2004; 111: 543-547.
- Mullan PB, Gorski JJ, Harkin DP. *BRCA1* – a good predictive marker of drug sensitivity in breast cancer treatment? *Biochim Biophys Acta* 2006; 1766: 205-216.
- Husain A, He G, Venkatraman ES, Spriggs DR. *BRCA1* up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). *Cancer Res* 1998; 58: 1120-1123.
- Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of *BRCA1* leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. *Oncogene* 2001; 20: 6597-6606.
- Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. *BRCA1* expression modulates chemosensitivity of *BRCA1*-defective HCC1937 human breast cancer cells. *Br J Cancer* 2003; 88: 1285-1291.
- Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2* related breast cancer. *J Med Genet* 2002; 39: 608-610.
- Delaloge SPP, Kloos I, et al. *BRCA1*-linked breast cancer (BC) is highly more chemosensitive than its *BRCA2*-linked or sporadic counterparts. Program and Abstracts of the 27<sup>th</sup> Congress of the European Society for Medical Oncology 2002; Abstract 120.
- Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with *BRCA*-associated ovarian carcinoma. *Cancer* 2003; 97: 2187-2195.
- Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. Clinical outcomes of breast cancer in carriers of *BRCA1* and *BRCA2* mutations. *N Engl J Med* 2007; 357: 115-123.
- Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD. Impact of germline *BRCA1* mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow-up data. *Cancer* 2003; 97: 527-536.
- Boland CR. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. *J Clin Oncol* 2007; 25: 754-756.
- Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. *Nature* 1993; 362: 652-654.
- Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. *Proc Natl Acad Sci USA* 1993; 90: 6424-6428.
- Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. *Cancer Res* 1995; 55: 3721-3725.
- Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M, Boland CR. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. *J Clin Invest* 1996; 98: 199-206.
- Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. *Cancer Res* 1996; 56: 3087-3090.
- Lynch HT, Boland CR, Gong G, Shaw TG, Lynch PM, Fodde R, Lynch JF, de la Chapelle A. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. *Eur J Hum Genet* 2006; 14: 390-402.
- Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med* 2003; 349: 247-257.
- Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. *Gastroenterology* 2004; 126: 394-401.

26. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, Cats A, Morreau H, Gelderblom H, Vasen HFA. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. *Int J Cancer* 2004; 109: 468-471.
27. Johnson L, Chu E. Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability. *Clin Colorectal Cancer* 2002; 2: 146-148.
28. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HFA, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; 96: 261-268.
29. Fallik D, Borini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC, Ducreux M, Praz F. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. *Cancer Res* 2003; 63: 5738-5744.
30. Boyd J, Sonoda Y, Federici MG, Bogomolny F, Rhei E, Maresco DL, Saigo PE, Almadrone LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poyner EA, Hoskins WJ. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. *JAMA* 2000; 283: 2260-2265.
31. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2007; 25: 2741-2746.
3. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod S, Lubinski J. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. *Breast Cancer Res Treat* 2007; May 10 [Epub ahead of print].
4. Lubiński J, Górski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fernández P, Domagała W, Chosia M, Uciński M, Grzybowska E, Lange D, Maka B, Mackiewicz A, Karczewska A, Breborowicz J, Lamperska K, Stawicka M, Gozdecka-Grodecka S, Bebenek M, Sorokin D, Wojnar A, Haus O, Sir J, Mierzwa T, Niepsuj S, Gugala K, Gózdź S, Sygut J, Kozak-Klonowska B, Musiatowicz B, Posmyk M, Kordek R, Morawiec M, Zambrano O, Waśko B, Fudali L, Skret J, Surdyka D, Urbański K, Mitus J, Ryś J, Szwiec M, Rozmiarek A, Dziuba I, Wandzel P, Wiśniowski R, Szczyluk C, Kozak A, Kozłowski W, Narod SA. BRCA1-positive breast cancers in young women from Poland. *Breast Cancer Res Treat* 2006; 99: 71-76.

**Pax H.B. Willemse<sup>1</sup>, Rolf H. Sijmons<sup>2</sup>**

<sup>1</sup>Department of Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands  
<sup>2</sup>Department of Genetics, University Medical Centre Groningen, Groningen, the Netherlands

## Walter Weber

Medical Oncology, Heuberg 16, CH – 4051 Basel, Switzerland,  
 e-mail: cancer@bluewin.ch

### *BRCA1* and taxanes

Neo-adjuvant chemotherapy means the use of chemotherapy initially in patients with localized solid tumours with the intent of increasing the potential for local control by surgery and radiotherapy and delivering the earliest possible treatment to micrometastatic disease [1]. This modality provides a unique opportunity to identify molecular predictors of response to treatment in breast cancer. Inclusion of taxanes in preoperative chemotherapy improves pathologic response rates [2]. This may not be the case in breast cancer patients with *BRCA1* germline mutations [3]. Therefore *BRCA1* testing should be considered for neo-adjuvant breast cancer chemotherapy trials incorporating taxanes. Pilot studies could be started in populations with founder mutations, e.g. Poland, where *BRCA1* testing can be done rapidly at a low price [4].

## References

1. Frei E 3rd. What's in a name – neoadjuvant. *J Natl Cancer Inst* 1988; 80: 1088-1089.
2. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy

improves pathologic complete response rate in estrogen receptor-positive breast cancers. *Ann Oncol* 2007; 18: 874-880.

Testing breast cancer patients for *BRCA1* mutations is not necessarily a good step and various aspects (medical, psychological, socio-legal) may make patients decide for or against testing. If, however, knowing the *BRCA1* mutation status were important in choosing the type of treatment, then a strong argument in favour of testing would need to be discussed with these patients, or, depending on the resources available, with only the subset that have a significant chance of carrying a *BRCA1* mutation.

Although *in vitro* studies of *BRCA1*-associated breast cancers have demonstrated increased sensitivity to DNA-damaging agents like mitomycin C and platinum, and resistance to mitotic-spindle poisons, such as taxanes, there is a paucity of clinical studies to support these findings [reviewed in 1]. Byrski et al. have now reported the response to neo-adjuvant chemotherapy of breast cancer in a small retrospective study of *BRCA1* mutation carriers and matched controls. They observed a lower response to taxane in the *BRCA1* group compared with controls. Together, these *in vitro* and clinical observations suggest that the *BRCA1* mutation carrier status could be relevant to the choice of chemotherapeutic agents in the treatment of breast cancer. However, larger and prospective clinical studies are needed to explore this issue more fully. At this time, outside research settings, we would therefore not recommend *BRCA1* mutation analysis in breast cancer patients for the purpose of choosing between the different chemotherapeutic agents available.



## References

1. Cleator S, Heller W, Coombes RC. Review. Triple-negative breast cancer: therapeutic options. *Lancet Oncology* 2007; 8: 235-244.

## Piotr J. Wysocki

**University School of Medical Sciences and Great Poland Cancer Centre, Department of Cancer Immunology, Poznan, Poland**

Taxane-based treatment of breast cancer patients in neoadjuvant or adjuvant setting is still rare in Poland. The National Health Fund permits administration of taxane-containing chemotherapy regimens in locally-advanced breast cancer without providing additional funds. In the Great Poland Cancer Centre in Poznan, Poland, which is a main oncology centre in western Poland (~1100 new breast cancer cases diagnosed each year), taxane-based adjuvant regimens are not routinely administered. The standard chemotherapy regimens in locally advanced breast cancer administered in our centre are anthracycline-containing regimens – AC or FAC.

In the forthcoming months in the Great Poland Cancer Centre we plan to introduce a routine evaluation of *BRCA1* gene status in all newly diagnosed breast cancer patients prior to initiation of systemic treatment.

For a few years the National Health Fund has been providing separate funds for treatment of metastatic breast cancer patients with taxane-based chemotherapy. Since there are significant numbers of patients receiving such a systemic therapy, a routine evaluation of *BRCA1* gene status prior to initiation of this treatment should be considered. This procedure may identify patients who would not benefit from the taxane-based chemotherapy and for whom other cytotoxic drugs in a first-line treatment would be potentially more effective.

Your proposal mainly focuses on patients with locally-advanced breast cancer prior to initiation of a neoadjuvant systemic treatment. Despite the lack of studies evaluating the influence of *BRCA1* gene mutations on the efficacy of adjuvant taxane-based chemotherapy I think in the case of patients with a defective *BRCA1* gene, administration of taxanes following surgery should be restricted.

During the last decade several clinical trials evaluating the efficacy of adjuvant taxanes in breast cancer patients have been conducted. In many of the trials Polish oncology centres were actively involved. Patients enrolled in such studies must have a complete pathological and clinical background and are very tightly controlled during the treatment period and in the follow-up. Therefore I think it may be worth obtaining clinical data of breast cancer patients treated

in Poland with adjuvant taxanes in clinical studies and make an effort to obtain patients' biological samples that will allow analysis of *BRCA1* gene status. Based on such information a reliable, retrospective clinical analysis would be feasible.

## Vladimir Zajac

**Cancer Research Institute, Slovak Academy of Sciences, Laboratory of Cancer Genetics, Bratislava, Slovak Republic**

### Opinion on article of the authors Byrski et al.: Response to neo-adjuvant chemotherapy in women with *BRCA1*-positive breast cancer

The article is very interesting and the results are important. There are not many clinical data about the effect of chemotherapy of patients with hereditary form of breast and ovarian cancer induced by mutations in the *BRCA1* gene. The results of the study are in agreement with pre-clinical data, which show that chemotherapy based on taxanes has no importance for breast cancers in *BRCA1* mutation carriers.

#### Limitations:

- retrospective study, patient selection, possibility of retroaction of the aims of the study on the basis of results,
- case-control study with relatively low number of patients (but in this diagnosis it is rather sizable),
- the search effect is debilitated by the many different schemes of therapy,
- because of combination of anthracycline and taxane it is not possible to expressly consider effect of taxanes.

#### Conclusion:

I evaluate the presented study as positive and the results achieved are the basis for realization of a prospective study.

## Zheng Shu

**Cancer Institute, Second Affiliated Hospital, Zhejiang University, Hangzhou, China**

Breast cancer is the main cancer of women worldwide. Chemotherapy is one kind of the main combination treatment. How to reasonably select a suitable high response regimen is an important issue for the clinic. Neo-adjuvant chemotherapy may differ in efficiency between hereditary *BRCA1* mutation carriers and a sporadic subgroup (non-carriers). Preclinical studies have indicated that intact *BRCA1* protein is required for the desired cell response to taxol in cell lines.

From this point of view, the authors speculated that breast tumours that lack *BRCA1* protein may be resistant to taxane-based chemotherapies. They designed the retrospective study with Poland registration data. A total of 3,136 patients with patho-clinical record and blood samples were collected. The blood was analyzed for founder mutations in *BRCA1*. The 44 *BRCA1* mutation carrier cases received neo-adjuvant chemotherapy, and there were 41 matched mutation-negative breast cancer as control cases. The authors compared the different regimens' (CMF, CMFP, AC, FAC, and **AT**) response between the *BRCA1* mutation carriers and non-carriers, comparing also between the two subgroups' response to the taxane-based regimen. The results are very interesting and impressive as follows:

- the 15 *BRCA1* mutation carriers were given docetaxel, only 6 of 15 had a response (CR or PR); for comparison 12 of 12 non-carriers had complete or partial response;
- all the remaining 29 *BRCA1* mutation carries had a CR or PR with other treatment regimens; they did not show chemotherapy resistance during the neo-adjuvant period.

In this study even though the number of the cases is small, it really remained the clinician to design a further prospective study. Before the operation get the blood to analyse the *BRCA1* status and ER status with core aspiration biopsy.